Donor-receptor coupled oligoelectrolytes and their use for cell labeling

Conjugated oligoelectrolytes serve as fluorescent membrane probes in flow cytometry, addressing issues of weak fluorescence and selectivity, achieving improved cell analysis and detection.

JP7948639B2Active Publication Date: 2026-11-11NATIONAL UNIVERSITY OF SINGAPORE
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2024508679
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-08-16
Filing Date
2022-08-16
Publication Date
2026-11-11
Estimated Expiration
2042-08-16

Smart Images

  • Figure 0007948639000085
    Figure 0007948639000085
  • Figure 0007948639000086
    Figure 0007948639000086
  • Figure 0007948639000087
    Figure 0007948639000087
Patent Text Reader

Abstract

The present disclosure relates to compounds of formula (I) and methods of use thereof. [Formula 1] TIFF2024534774000114.tif13170 The compounds of formula (I) are conjugated oligoelectrolytes and are suitable for use as membrane probes for labeling and / or detecting cells and / or lipid vesicles, and are therefore suitable for flow cytometry applications. The present disclosure also relates to a flow system for detecting and / or quantifying cells and / or lipid vesicles.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] field This disclosure relates to a conjugated oligoelectrolyte and a method of using the same. In particular, the conjugated oligoelectrolyte is suitable for use as a membrane probe and is therefore suitable for flow cytometry applications. [Background technology]

[0002] background Flow cytometry is a high-throughput experimental technique for rapidly counting, recognizing, and sorting individual cells, microorganisms, and particles. It is used in clinical and research characterization across many disciplines, including cancer biology, immunology, microbiology, and virology. Flow cytometry utilizes a microfluidic system in which individual cells or particles flow into a flow, rapidly pass through a laser light source, and are then analyzed by fluorescence or light scattering. Fluorescent proteins, fluorescently labeled antibodies, or structure-specific dyes, such as those specific to DNA or lipid membranes, can be used to measure the unique properties of individual cells or particles. Fluorescence labeling is important for a variety of purposes, to name a few, including understanding cell viability, identifying various cell types in heterogeneous mixtures, measuring antigen or protein expression, cell cycle analysis, and understanding membrane integrity.

[0003] Because flow cytometry heavily relies on fluorescent tags, technicians may face numerous problems depending on the fluorescent labels used, or if multiple labels are required. For example, fluorescence intensity may be weak, or the fluorescent labels may degrade upon exposure to light. Furthermore, recognition probes may have few fluorophore binding sites or a limited number of effective dyes. Binding between the fluorescent label and the desired cellular component may be weak. When the fluorescent label is not properly internalized by the cell, the fluorescence signal may become excessively saturated. Under inappropriate incubation conditions, the fluorescent label may aggregate and therefore self-quench. Also, high background or nonspecific staining can interfere with the analysis. When two or more fluorescent labels are used, overlapping signals can lead to confusing and even uninterpretable results. Additionally, some fluorescent labels are toxic to cells, and therefore only short working time slots are allocated for flow cytometry.

[0004] Therefore, there is a need for molecules that can function as fluorescent labels or fluorescent dyes for use in flow cytometry. Furthermore, there is a need for fluorescent molecules that can preferentially target microorganisms, especially bacterial cells.

[0005] Therefore, it would be desirable to overcome or improve at least one of the above problems. [Overview of the Initiative]

[0006] overview The present invention is based on the discovery that certain conjugated oligoelectrolytes (COEs) exhibit distinct membrane association, and are thus advantageous for use as fluorescent membrane probes. In particular, the present inventors have discovered that when the conjugated moieties along the backbone of a COE are modified, the emitted fluorescent signal can be tuned to a specific wavelength. Furthermore, the Stokes shift (the difference between peak excitation and peak emission) can be adjusted. By further modifying the pendant chains at the termini of the conjugated backbone, the selectivity for specific cell membranes can be tuned. The penetration of these COE compounds into cell membranes enables cells, liposomes, vesicles, and other membrane-containing macrostructures to be analyzed using flow cytometry.

[0007] The present invention provides a compound of Formula (I), or a salt or solvate thereof:

Chemical Formula

Chemical Formula

[0008] The conjugated compound of formula (I) comprises a composition of structural units in which donor (D) / acceptor (A) alternate with each other, so that the luminescence, quantum yield, and Stokes shift can be adjusted over a much wider range than those dependent only on the π-conjugation of polyalkenylene or polyphenylalkenylene. Furthermore, the molecular topology of the molecule enables rapid self-assembly in membranes of various cell types and lipid types. A specific molecular fragment, such as phenylene, can be a monomer unit D or a monomer unit A depending on the electron affinity or ionization potential of adjacent groups.

[0009] In some embodiments, A is an electron-accepting moiety.

[0010] In some embodiments, A is Formula selected from, wherein in the formula, Formula This represents a bond to D or to L2; Each X1 is independently selected from C, O, N, S, and Se; Each X2, if present, is independently selected from C, O, N, S, and Se; If X2 exists, then at least one of X1 and X2 is O, N, or S; Each R is independently selected from H, halo, cyano, and optionally substituted alkyl groups.

[0011] In some embodiments, A is part of equation (II): [ka] During the ceremony, [ka] This represents a bond to D or to L2; R2, R3, R4, and R5 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R2 and R3 are linked together to form a heterocycline, heteroaryl, or which may be substituted; R4 and R5 are linked together to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0012] In some embodiments, A is

[0013] [ka] Herein, R4 and R5 are as disclosed herein.

[0014] In some embodiments, A is [ka] That is the case.

[0015] In some embodiments, D is an electron-donating portion.

[0016] In some embodiments, D is [ka] This is the part selected from, in the formula, [ka] This represents a bond to A or to L2; Each X1 is independently selected from C, O, N, S, and Se; Each X2, if present, is independently selected from C, O, N, S, and Se; If X2 exists, then at least one of X1 and X2 is O, N, or S; R is independently selected from H, halo, cyano, and optionally substituted alkyl groups.

[0017] In some embodiments, D is a substituted five-membered heteroarylene.

[0018] In some embodiments, D is part of equation (III): [ka] In the formula, Y is NR, O, or S; R6 and R7 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R6 and R7 are linked to form optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; R is selected from H, halo, cyano, and optionally substituted alkyl groups.

[0019] In some embodiments, D is [ka] Herein, R6 and R7 are as disclosed herein.

[0020] In some embodiments, D is [ka] That is the case.

[0021] In some embodiments, L1 is [ka] Selected from.

[0022] In some embodiments, each R1 is independently selected from an optionally substituted alkyl group or an optionally substituted alkoxy group.

[0023] In some embodiments, each R1 may be independently selected from alkyl and alkoxy and substituted with amino or alkylamino, respectively.

[0024] In some embodiments, each R1 is independently a C3-C8 alkoxy substituted with an amino or alkylamino.

[0025] In some embodiments, the optional substituent of L1 is independently selected from halogens, cyanos, optionally substituted alkyls, optionally substituted alkenyls, or optionally substituted alkynyls.

[0026] In some embodiments, the compound of formula (I) is the compound of formula (Ia): [ka] In the formula, L1, A, D, R1, n, m, and q are as disclosed herein.

[0027] In some embodiments, the compound of formula (I) is the compound of formula (Ib): [ka] In the formula, L1, A, D, R1, n, m, and q are as disclosed herein.

[0028] In some embodiments, the compound of formula (I) is the compound of formula (Ib), where, A is part of equation (II): [ka] During the ceremony, [ka] This represents a bond to D or to L2; R2, R3, R4, and R5 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R2 and R3 are linked together to form a heterocycline, heteroaryl, or which may be substituted; R4 and R5 are linked to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; D is part of equation (III): [ka] In the formula, Y is NR, O, or S; R6 and R7 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R6 and R7 are linked together to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0029] In some embodiments, the compound of formula (I) is the compound of formula (Ib), where, A is [ka] In the formula, R4 and R5 are as disclosed herein; D is [ka] Herein, R6 and R7 are as disclosed herein.

[0030] In some embodiments, the compound of formula (I) is the compound of formula (Ic): [ka] Each R1 is independently selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aminoacyloxy, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted thio, or optionally substituted phosphoryl; R2, R3, R4, and R5 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R2 and R3 are linked together to form a heterocycline, heteroaryl, or which may be substituted; R4 and R5 are linked to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; R6 and R7 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R6 and R7 are linked to form optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each R8 is independently selected from halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; Y is NR, O, or S; Each p is an integer independently selected from 0 to 4; q is an integer selected from 1 to 5; q' is an integer selected from 1 to 5.

[0031] In some embodiments, the compound of formula (I) is the compound of formula (Id): [ka] In the formula, R1, R4, R5, R6, R7, R8, Y, p, q, and q' are as disclosed herein.

[0032] In some embodiments, the compound of formula (I) is the compound of formula (Ie): [ka] In the formula, R1, R4, R5, R6, R7, R8, p, q, and q' are as disclosed herein.

[0033] In some embodiments, the compound of formula (I) is the compound of formula (If): [ka] In the formula, R4, R5, R6, R7, R8, R9, p, q, and q' are as disclosed herein; Each R9 is independently H or an optionally substituted alkyl group; Each t is an integer independently selected from 1 to 8.

[0034] In some embodiments, the compound of formula (I) is [ka] Selected from.

[0035] The present invention also provides compounds of formula (Ig), or salts or solvates thereof: [ka] During the ceremony, Each R1 is independently selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aminoacyloxy, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted thio, or optionally substituted phosphoryl; q is an integer selected from 1 to 5; q is an integer selected from 1 to 5; r is an integer selected from 1 to 5.

[0036] The present invention also relates to a method for labeling cells and / or lipid vesicles, a) A method is provided comprising the step of incubating compounds of formula (I), subformulas (Ia-Ig), or salts or solvates thereof with cells and / or lipid vesicles.

[0037] The present invention also relates to a method for detecting cells and / or lipid vesicles using a fluorescence detector, a) A step of incubating a compound of formula (I), subformulas (Ia-Ig), or a salt or solvate thereof with cells and / or lipid vesicles; and b) The process of passing the cells through a fluorescence detector. This provides a method that includes [something].

[0038] The present invention also relates to a method for detecting cells and / or lipid vesicles using a flow cytometer, a) Equation (IV); [ka] (In the formula, R1 is independently selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aminoacyloxy, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted thio, or optionally substituted phosphoryl; R2 is independently selected from halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; u is an integer selected from 3 to 15; Each s is an integer independently selected from 0 to 4; q is an integer selected from 2 to 5; (q' is an integer selected from 2 to 5) The steps of incubating the compound, or a salt or solvate thereof, with cells and / or lipid vesicles; and b) The process of flowing cells and / or lipid vesicles through a flow cytometer. This provides a method that includes [something].

[0039] In some embodiments, the cells and / or lipid vesicles are in a suspended state.

[0040] In some embodiments, the cells are adherent cells.

[0041] In some embodiments, the incubation period ranges from approximately 1 minute to approximately 12 days.

[0042] In some embodiments, cells and / or lipid vesicles are passed through a flow cytometer without any purification steps.

[0043] In some embodiments, compounds of formula (I), subformulas (Ia to Ig), and / or formula (IV) exhibit fluorescence excitation at wavelengths of approximately 300 nm to 1000 nm.

[0044] In some embodiments, compounds of formula (I), subformulas (Ia to Ig), and / or formula (IV) exhibit fluorescence emission at wavelengths of approximately 300 nm to 2000 nm.

[0045] In some embodiments, cells and / or lipid vesicles incubated with compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV) exhibit luminescence intensity approximately 2 to 500 times greater than that of control samples of compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV).

[0046] In some embodiments, the method further includes the step of contacting cells and / or lipid vesicles with another dye.

[0047] The present invention also relates to a flow system for detecting and / or quantifying cells and / or lipid vesicles, a) Compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or salts or solvates thereof, for labeling cells and / or lipid vesicles; b) An entry point for introducing labeled cells and / or lipid vesicles into the flow system; c) Inlet and fluid-communicated detection means for detecting fluorescence emission from labeled cells and / or lipid vesicles; and The present invention provides a flow system that optionally includes d) a counting means for quantifying labeled cells and / or lipid vesicles.

[0048] Hereinafter, embodiments of the present invention will be described as non-limiting examples with reference to the drawings. [Brief explanation of the drawing]

[0049] [Figure 1] Examples of the conjugated oligoelectrolytes of the present invention are shown. [Figure 2] Flow cytometry measurements using compounds of formula (I) and / or formula (IV) for selective labeling of Gram-positive bacteria from Gram-negative bacteria are shown. [Figure 3] Flow cytometry measurements of compounds (a-f) of formula (I) and / or formula (IV), as well as unlabeled exosomes (h), are shown. [Figure 4] Flow cytometry measurements of exosomes labeled with compounds of formula (I) and / or formula (IV) are shown. [Figure 5] TEM images of exosomes (a), exosomes labeled with compounds of formula (I) and / or formula (IV) (b), and exosomes labeled with compounds of formula (I) and / or formula (IV) and collected after FACS (c) are shown. [Figure 6] Flow cytometry measurements of RBCs labeled with the compounds of formula (I) and / or formula (IV) are shown. [Figure 7] This shows the proportion of flow cytometry events occurring in the gating region of RBCs labeled with compounds of formula (I) and / or formula (IV) in various ratios versus unstained RBCs. [Figure 8] Flow cytometry measurements of Hep-G2 cells labeled with compounds of formula (I) and / or formula (IV) are shown. [Figure 9] This shows the proportion of flow cytometry events occurring in the gating region of Hep-G2 stained with compounds of formula (I) and / or formula (IV) in various ratios compared to unstained Hep-G2. [Figure 10]Flow cytometry measurements are shown for two separate populations of A549 cells: those labeled with the compound of formula (I) and / or formula (IV), and unlabeled cells. [Figure 11] Flow cytometry measurements of passaged A549 cells labeled with the compound of formula (I) and / or formula (IV) are shown. [Figure 12] Confocal micrographs of HepG2 cells after staining with 4 μM of the compound of formula (I) and 4 μM of the commercially available membrane dye FM 4-64 are shown: (a) channel of the compound of formula (I), (b) FM 4-64 channel, (c) bright-field channel, (d) integrated channel. Scale bar is 20 μm. [Figure 13] Fluorescence microscopy images of A549 cells stained with compounds of formula (I) and / or formula (IV) are shown. [Figure 14] (a-b) SUV, compounds of formula (I) and / or formula (IV) in PBS buffer, and combinations of SUV and said compounds in PBS buffer; (c) Photoluminescence (PL) spectra of the three compounds of formula (I) and / or formula (IV) showing various emission peaks after the addition of SUV in PBS. [Figure 15] The following shows various emission wavelengths of compounds of formula (I) and / or formula (IV). [Figure 16] The dynamic light scattering particle size distribution curves with respect to intensity are shown for liposomes not labeled with the compound of formula (I) and / or formula (IV) (gray solid line) and liposomes labeled with the compound (dark dashed line). [Figure 17] The particle size distribution plots for the dye-only control and their corresponding gated dot plots are shown. [Figure 18] The particle size distribution plots of COE-labeled SW480 exosomes (10 μM) and their corresponding gated dot plots are shown. [Figure 19]The particle size distribution plots of dye-labeled SW480 exosomes (10 μM and 20 μM) after removal of excess dye using ultracentrifugation, and their corresponding gated dot plots, are shown. [Figure 20] This paper presents imaging flow cytometry images of A549 cells stained with COE-Ben-stained exosomes at various treatments and time points, as well as their corresponding flow cytometry analyses. [Figure 21] The images show colocalization micrographs of A549 cells that were incubated with 2 μM COE-BT and then stained with early or late endosome-GFP reagent (BacMam 2.0) or 100 nM lysosome-specific dye LysoTracker® Green DND-26. [Figure 22] Transmission electron microscope images of EVs secreted from COE-BT-stained A549 cells, and flow cytometry analysis of EVs secreted from COE-BT-stained A549 cells after the first 24 hours of incubation are shown. [Figure 23] Figures 23a-b show photographs and absorption spectra of 50 μM COE or DiR solutions in PBS before and after ultrafiltration. [Figure 24] The correlation coefficient curves and average count rates derived from the DLS measurements are shown for pure PBS, 1 μM COE-BT, 1 μM DiR, or 1 mM SUV in PBS, or 1 μM of other COE in PBS, as measured by dynamic light scattering (DLS). [Figure 25] The images show the Tyndall effect of pure PBS or 10 μM COE in PBS after illumination using a red laser pointer. [Figure 26] The images show 200 μL of COE solution and 200 μL of dye solution in PBS in a 96-well microplate before and after standing for 16 hours at room temperature. [Figure 27]Flow cytometry measurements of COE-BT stained and COE-Ben stained SUV (130 nm) mixtures incubated in PBS at various mixing ratios for 1 hour and 24 hours, and analyzed with Cytoflex, are shown. [Figure 28] Figure 27 shows the proportion of SUVs in various gates after 1 hour or 24 hours of mixing. [Figure 29] The dot plot profiles of dye-positive events are shown for POPC liposomes with particle sizes of 100 nm, 200 nm, 400 nm, and 800 nm, labeled with 0.5 mol% COE-Ben and COE-BT, analyzed with Cytoflex. [Figure 30] The image shows a confocal micrograph of 6.25 mg mL-1 LMV (large multilayer vesicle) after staining with 15 μM COE-Ben and 15 μM FM 4-64 in PBS at room temperature for 30 minutes. The contrast curves represent the fluorescence intensity profiles of the white lines in the fluorescence micrograph of both channels on the left. [Figure 31] The images show COE samples with and without (-) treatment with 1 mM SUV in PBS under ultraviolet (365 nm) irradiation using a portable UV lamp. [Figure 32] Zeta potential measurements of SUVs of 1 mM POPC only, stained with various COEs at 5 μM in DI water, as well as the Z-mean diameter and PDI measured by DLS of SUVs of 1 mM POPC only, stained with various COEs at 5 μM in DI water. [Figure 33] Confocal micrographs of fresh red blood cells (RBCs) are shown: (a) unstained, (b) labeled with 2 μM COE-S6, and (c) labeled with 1 μg / mL Cell Mask Deep Red. [Figure 34] Confocal micrographs of red blood cells (RBCs) stored for 22 days are shown, (a) unstained, (b) labeled with 2 μM COE-S6, and (c) labeled with 1 μg / mL Cell Mask Deep Red. [Figure 35](a-c) FSC / SSC dot plots of unstained, 1 μM COE-S6-labeled, and 0.5 μg mL-1 Cell Mask Deep Red-labeled erythrocytes (RBCs) measured by flow cytometry, (d) a histogram showing the increase in fluorescence when RBCs are labeled with gradually increasing concentrations of COE-S6, and (e) a histogram showing the decrease in fluorescence due to quenching effect when RBCs are labeled with gradually increasing concentrations of Cell Mask Deep Red. The coefficient of variation (CV) of the histogram data is shown in (f). [Figure 36] Flow cytometry measurements of COE-BBT-stained A549 cells, obtained by excitation using an 808 nm laser and collection of emission using a 950 nm long-pass filter, are shown. Unstained A549 cells were used as a negative control. [Figure 37] The measured cytotoxicity of COE against A549 cells is shown. [Figure 38] This shows the measured hemolysis of COE against bovine erythrocytes in PBS. [Modes for carrying out the invention]

[0050] Detailed explanation "Alkyl" refers to a monovalent alkyl group that can be linear or branched and preferably has 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms. Examples of these alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and n-hexyl.

[0051] "Alkenyl" refers to a monovalent alkenyl group that can be linear or branched, preferably having 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, and having at least one, preferably 1 to 2, carbon-to-carbon double bonds. Examples include ethenyl (-CH=CH2), n-propenyl (-CH2CH=CH2), isopropenyl (-C(CH3)=CH2), and buta-2-enyl (-CH2CH=CHCH3).

[0052] "Alkynyl" refers to an alkynyl group having preferably 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, and having at least one, preferably 1 to 2, carbon-to-carbon triple bonds. Examples of alkynyl groups include ethynyl (-C≡CH), propargyl (-CH2C≡CH), and penta-2-inyl (-CH2C≡CCH2-CH3).

[0053] "Alkoxy" refers to an alkyl-O-group whose alkyl group is as described above. Examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0054] "Alkenyloxy" refers to an alkenyl-O- group, where the alkenyl group is as described above.

[0055] "Alkynyloxy" refers to the alkynyl-O- group, which is defined as an alkynyl group as described above.

[0056] "Halo" or "halogen" refers to fluoro, chloro, bromo, and iodine.

[0057] "Acyl" means an HC(O)-group, alkyl-C(O)-group, cycloalkyl-C(O)-group, cycloalkyl-C(O)-group, aryl-C(O)-group, heteroaryl-C(O)-group, and heterocyclyl-C(O)-group, as described herein, where alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are defined as such.

[0058] "Oxyacyl" means an HOC(O)-group, alkyl-OC(O)-group, cycloalkyl-OC(O)-group, cycloalkyl-OC(O)-group, aryl-OC(O)-group, heteroaryl-OC(O)-group, and heterocyclyl-OC(O)-group, where alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are as described herein.

[0059] "Amino" means an -NR''R'' group in which each R'' independently is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, where alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are as described herein, respectively.

[0060] "Aminoacyl" means a -C(O)NR''R'' group in which each R'' is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, where alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are as described herein.

[0061] "Acylamino" means an -NR''C(O)R'' group in which each R'' is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, where alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are as described herein.

[0062] "Acyloxy" means -OC(O)-alkyl, -OC(O)-aryl group, -C(O)O-heteroaryl group, and -C(O)O-heterocyclyl group, where alkyl, aryl, heteroaryl, and heterocyclyl are as described herein.

[0063] "Aminoacyloxy" means -OC(O)NR''-alkyl group, -OC(O)NR''-aryl group, -OC(O)NR''-heteroaryl group, and -OC(O)NR''-heterocyclyl group, where R'' is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, and alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are as described herein, respectively.

[0064] "Cyano" refers to the -CN group.

[0065] "Oxyacylamino" means -NR''C(O)O-alkyl group, -NR''C(O)O-aryl group, -NR''C(O)O-heteroaryl group, and NR''C(O)O-heterocyclyl group, where R'' is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, and alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are as described herein, respectively.

[0066] "Oxyacyloxy" means -OC(O)O-alkyl groups, -OC(O)O-aryl groups, -OC(O)O-heteroaryl groups, and -OC(O)O-heterocyclyl groups, where alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are as described herein.

[0067] "Thio" means an HS- group, alkyl-S- group, cycloalkyl-S- group, aryl-S- group, heteroaryl-S- group, and heterocyclyl-S- group, as described herein, where alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl are defined as such.

[0068] "Phosphoryl" means a -P(O)(R''')(OR'''') group, where R'''' represents OR'''' or is hydroxyl, alkyl, or amino, and R'''' is alkyl, cycloalkyl, aryl, or arylalkyl, with alkyl, amino, alkenyl, aryl, cycloalkyl, and arylalkyl being as described herein.

[0069] "Aryl" refers to an unsaturated aromatic carbocyclic group having one ring (e.g., phenyl) or multiple fused rings (e.g., naphthyl or anthryl), preferably having 6 to 14 carbon atoms. Examples of aryl groups include phenyl and naphthyl.

[0070] "Heteroaryl" refers to a monovalent aromatic heterocyclic group that satisfies Hückel's rule for aromaticity (i.e., contains 4n+2 π electrons) and preferably has 2 to 10 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen, selenium, and sulfur in its ring (including sulfur, selenium, and nitrogen oxides). These heteroaryl groups may have one ring (e.g., pyridyl, pyrrolyl, or their N-oxides, or furyl) or multiple fused rings (e.g., indolidinyl, benzimidazolyl, coumarinyl, quinolinyl, isoquinolinyl, or benzothienyl).

[0071] Examples of heteroaryl groups include, but are not limited to, oxazole, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indidine, isoindole, indole, indazole, purine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carborin, phenantholidine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, isothiazole, phenoxazine, phenothiazine, thiazole, thiadiazole, oxadiazole, oxatriazole, tetrazole, thiophene, benzo[b]thiophene, triazole, and imidazopyridine.

[0072] "Arylene" refers to a divalent aryl group as described above.

[0073] "Heteroarylene" refers to a divalent heteroaryl group in which the aryl group is as described above.

[0074] A "heterocyclyl" means a monovalent saturated or unsaturated group having one or more fused rings, preferably containing 1 to 8 carbon atoms and 1 to 4 heteroatoms selected from nitrogen, sulfur, oxygen, selenium, or phosphorus within the ring. The most preferred heteroatom is nitrogen. For example, if R2 or R' is a substituted heterocyclyl having one or more ring heteroatoms, it will be understood that the heterocyclyl group may be connected to the core molecule of the compound of the present invention through CC or C-heteroatom bonds, particularly CN bonds.

[0075] Examples of heterocyclyl and heteroaryl groups include oxazole, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indidine, isoindole, indole, indazole, purine, quinoridine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenantholidine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, isothiazole Examples include, but are not limited to, zoles, fenoxazines, phenothiazines, imidazolidines, imidazolines, piperidines, piperazines, indolines, phthalimides, 1,2,3,4-tetrahydroisoquinolines, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazoles, thiadiazoles, oxadiazoles, oxatriazoles, tetrazoles, thiazolidines, thiophene, benzo[b]thiophene, morpholino, piperidinil, pyrrolidine, tetrahydrofuranil, and triazoles.

[0076] "May be substituted" means that one group is hydroxyl, acyl, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, alkynyloxy, amino, aminoacyl, thio, arylalkyl, arylalkoxy, aryl, aryloxy, carboxyl, acylamino, cyano, halogen, nitro, phosphono, sulfo, phosphorylamino, phosphinyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, oxyacyl, oxime, oxime ether, hydrazone, oxyacylamino, oxysulfonylamino, aminoacyloxy, trihalomethyl, trialkylsilyl, pentafluoroethyl, trifluoromethoxy The term "optionally substituted amino" may be further substituted or unsubstituted with one or more groups selected from difluoromethoxy, trifluoromethanethio, trifluoroethenyl, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-heteroarylamino, mono- and di-heterocyclylamino, and asymmetric disubstituted amines having various substituents selected from alkyl, aryl, heteroaryl, and heterocyclyl, and may be condensed or uncondensed with them (to form a condensed polycyclic group), and may include bonding to a solid support material (for example, it may be substituted to a polymer resin). For example, the "optionally substituted amino" group may include amino acid residues and peptide residues.

[0077] "Hydrophilicity" refers to a molecule or part that has a greater affinity for water, and therefore greater solubility, than for organic solvents. For example, the hydrophilicity of a compound can be quantified by measuring its partition coefficient between water (or a buffered aqueous solution) and water-immiscible organic solvents such as octanol, ethyl acetate, methylene chloride, or methyl tert-butyl ether. A compound can be considered hydrophilic if, after equilibration, its concentration in water is greater than its concentration in the organic solvent.

[0078] "Hydrophobic" refers to a molecule or part that has a greater affinity for, and therefore greater solubility for, an organic solvent than for water. For example, the hydrophobicity of a compound can be quantified by measuring its partition coefficient between water (or a buffered aqueous solution) and a water-immiscible organic solvent such as octanol, ethyl acetate, methylene chloride, or methyl tert-butyl ether. A compound can be considered hydrophobic if, after equilibration, its concentration in the organic solvent is greater than its concentration in water.

[0079] Conjugated oligoelectrolytes (COEs) are a class of molecules defined by a hydrophobic conjugated core having terminal polar ionic pendants. In certain embodiments, the hydrophobic and hydrophilic portions in a COE can be rationally designed as molecules in which both portions reflect the organization of hydrophilic and hydrophobic domains in the lipid bilayer. Typically, this structural design encompasses only unbranched internal structures with charged groups at both ends to facilitate the spontaneous insertion of the COE into the cell membrane, induced by electrostatic and hydrophobic interactions between the COE and lipids. The inventors hypothesized that fluorescence resulting from π-π conjugation in the backbone can be tuned to occur at various wavelengths across the entire electromagnetic spectrum, including the ultraviolet, visible, and infrared regions. This can be achieved by fine-tuning the photoelectronic properties of the conjugated core through structural induction. For example, the backbone conjugated π system can be tuned to achieve an emission wavelength range of 300–2000 nm based on the donor and acceptor portions. Fluorescence excitation, emission, and Stokes shift can be tuned to this end. Furthermore, COEs can be modified to exhibit selectivity for specific membranes through the functionalization of various chemical groups that control their membrane insertion ability. This results in target-specific functionality.

[0080] Characteristically, the fluorescence emission of COEs is significantly enhanced when COEs are inserted from an aqueous solution into a lipid bilayer. This "light-up" mechanism increases the signal-to-noise ratio of COEs when they are localized in the more hydrophobic environment of the lipid bilayer. Furthermore, COEs have a different chemical structure from many commercially available lipophilic dyes (which usually contain surfactant-like structures, i.e., one side of the molecule is hydrophobic and the other side is hydrophilic). These surfactant-like structures induce micelle-like aggregation in aqueous solutions. For example, the commonly used membrane dye PKH-26 has been shown to form aggregates with particle size and fluorescence intensity similar to small particles such as exosomes, thereby producing false positive signals. These phenomena can be avoided in the case of COEs because their emission is greatly enhanced after insertion into the lipid bilayer, i.e., the signal-to-noise ratio increases.

[0081] Therefore, the present invention provides a compound of formula (I), or a salt or solvate thereof: [ka] During the ceremony, Each R1 is independently selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aminoacyloxy, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted thio or optionally substituted phosphoryl; q is an integer selected from 1 to 5; q' is an integer selected from 1 to 5; Each L2 is independently selected from optionally substituted ethylene or optionally substituted phenylethylene; L1 is a π-conjugated core containing monomer units A and D: [ka] During the ceremony, Each A is independently selected from an optionally substituted alkenylene, an optionally substituted arylene, or an optionally substituted heteroarylene; Each D is independently selected from an optionally substituted alkenylene, an optionally substituted arylene, or an optionally substituted heteroarylene; n is an integer selected from 1 to 5; m is an integer selected from 1 to 5; * indicates a bond to another monomer unit or to L2; Monomer units A and D are bonded to each other in an alternating manner; The compound of formula (I) exhibits a substantially linear topology.

[0082] In some embodiments, A and D are not both alkenylenes. In other embodiments, A and D are not both phenylenes. In other embodiments, A and D are not both alkenylenes and phenylenes. In some embodiments, L1 is not butadienylene, polyalkenylene, phenylalkenylene, or polyphenylalkenylene.

[0083] In some embodiments, a compound of formula (I), or a salt or solvate thereof: [ka] During the ceremony, Each R1 is independently selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aminoacyloxy, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted thio or optionally substituted phosphoryl; q is an integer selected from 1 to 5; q' is an integer selected from 1 to 5; Each L2 is independently selected from optionally substituted ethylene or optionally substituted phenylethylene; L1 is a π-conjugated core containing monomer units A and D: [ka] During the ceremony, Each A is independently selected from cyano-substituted alkenylenes, optionally substituted monocyclic heteroarylenes, or optionally substituted condensed heteroarylenes; Each D is independently selected from alkenylene, phenylene, optionally substituted condensed arylene, optionally substituted monocyclic heteroarylene, or optionally substituted condensed heteroarylene; n is an integer selected from 1 to 5; m is an integer selected from 1 to 5; * indicates a bond to another monomer unit or to L2; Monomer units A and D are bonded to each other in an alternating manner; The compound of formula (I) exhibits a substantially linear topology.

[0084] A further advantage is that these compounds do not require bioconjugated chemical reactions, such as those needed to label antibodies, when used as fluorescent labels.

[0085] The compound of formula (I) exhibits a substantially linear topology. Topology refers to the molecular structure of a compound within the constraints of three-dimensional (3D) space. This linear topology has two nodes at its ends and lacks junction nodes. A linear topology is advantageous for facilitating lipid membrane insertion.

[0086] In some embodiments, the bond connecting monomer units A and D in L1 is substantially aligned along the longitudinal axis of the compound. In other embodiments, monomer units A and D in L1 are substantially aligned along the longitudinal axis of the compound. In this regard, the bond connecting monomer units A and D when off-center along the longitudinal axis of the compound is within the scope of the present invention.

[0087] The compound of formula (I) is linear in order to occupy its position within the lipid bilayer. In some embodiments, the compound is not branched, i.e., the monomeric unit extends along only one chain. In some embodiments, the compound of formula (I) is symmetrical. The symmetry of the compound can be described by at least one of 32 point groups. One point group describes all symmetric operations that can be performed on the molecule to produce a three-dimensional structure indistinguishable from the original three-dimensional structure. In this regard, in some embodiments, the compound of formula (I) is C 2v It has a point cloud.

[0088] In some embodiments, each L2 is independently selected from optionally substituted ethylene or optionally substituted phenylethylene. In other embodiments, L2 is independently [ka] Selected from the above, where * represents a bond to the monomer unit and to the terminal phenyl moiety in the compound of formula (I).

[0089] L1 is a π-conjugated core. A conjugated system is a system of connected p-orbitals with delocalized electrons in the molecule that generally lowers the overall energy of the molecule and increases its stability. Lone pairs, radicals, or carbenium ions can be part of this system. This system can be cyclic, acyclic, linear, or mixed.

[0090] In some embodiments, when L1 contains a 6-membered aryl or heteroaryl ring, or when L1 contains a condensed aryl or condensed heteroaryl ring having a 6-membered ring, the monomer unit is 1,4-conjugated on the 6-membered ring. In other embodiments, when L1 contains a 5-membered aryl or heteroaryl ring, or when L1 contains a condensed aryl or condensed heteroaryl ring having a 5-membered ring, the monomer unit is 1,4-conjugated or 2,5-conjugated on the 5-membered ring.

[0091] Alternatively, L1 may be represented by at least one monomer unit A and at least one monomer unit D. In some embodiments, the combination of n and m is an integer selected from 2 to 10, 3 to 10, 3 to 9, 3 to 8, 3 to 10, or 3 to 7.

[0092] In some embodiments, L1 is [ka] Selected from.

[0093] As described above, A and D may be the same part, such that L1 forms an alternating π-conjugated core. Alternatively, A and D may be different. Since L1 contains a composition of structural units in which the donor / receptor alternates (with each other), structures that do not have a composition in which the donor / receptor alternates attached are excluded from the scope of the present invention. For example, butadieniene, polyalkenylene, phenylalkenylene, and polyphenylalkenylene are excluded.

[0094] In some embodiments, the optional substituent of L1 is selected from halogens, cyanos, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted alkoxys, optionally substituted alkenyloxys, and optionally substituted alkynyloxys. In other embodiments, the optional substituent of D is selected from halogens, cyanos, alkyls, alkenyls, alkoxys, and optionally substituted alkynyls. In some embodiments, the optional substituent of L1 is independently selected from halogens, cyanos, optionally substituted alkyls, optionally substituted alkenyls, or optionally substituted alkynyls.

[0095] In this specification, monomer unit D refers to the electron-donating (electron-rich) portion in contrast to monomer unit A. In this respect, monomer unit A is the electron-withdrawing / accepting (electron-poor) portion. When arranged in order, the DA combination is a permutation of similar portions that are in a conjugated state (-D n -or-A n Compared to (-), it generates an intramolecular charge transfer excited state in which absorption and emission are further directed towards red.

[0096] In some embodiments, A is an electron-accepting moiety. An electron acceptor is a chemical entity that accepts electrons transferred from another moiety or compound. In some embodiments, A has an electron-accepting substituent. In other embodiments, A has an electron-withdrawing substituent.

[0097] In some embodiments, A is independently selected from substituted or substituted heteroarylenes. In some embodiments, A is independently selected from cyanosubstituted or substituted heteroarylenes. In some embodiments, the cyanosubstituted alkenylene is a monosubstituted or disubstituted alkenylene. In other embodiments, the substituted heteroarylene is a substituted monocyclic heteroarylene or a substituted condensed heteroarylene. The heteroarylene may be a 5-membered heteroarylene or a 6-membered heteroarylene. The heteroarylene may be a condensed heteroarylene. In some embodiments, the heteroarylene is a condensed 5,5-membered heteroarylene, a condensed 5,6-membered heteroarylene, a condensed 6,6-membered heteroarylene, a condensed 5,5,6-membered heteroarylene, a condensed 5,6,6-membered heteroarylene, a condensed 6,6,6-membered heteroarylene, a condensed 5,5,6,6-membered heteroarylene, a condensed 5,6,6,6-membered heteroarylene, or a condensed 6,6,6,6-membered heteroarylene.

[0098] In some embodiments, the optional substituent of A is selected from halogens, cyanos, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted alkoxys, optionally substituted alkenyloxys, and optionally substituted alkynyloxys. In other embodiments, the optional substituent of A is selected from halogens, cyanos, alkyls, alkenyls, alkoxys, and alkenyloxys.

[0099] In some embodiments, A is [ka] Selected from, in the formula, [ka] This represents a bond to D or to L2; Each X1 is independently selected from C, O, N, S, and Se; Each X2, if present, is independently selected from C, O, N, S, and Se; If X2 exists, then at least one of X1 and X2 is O, N, or S; R is independently selected from H, halo, cyano, and optionally substituted alkyl groups.

[0100] In some embodiments, A is part of equation (II): [ka] During the ceremony, [ka] This represents a bond to D or to L2; R2, R3, R4, and R5 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R2 and R3 are linked together to form a heterocycline, heteroaryl, or which may be substituted; R4 and R5 are linked together to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0101] In some embodiments, R2 and R3 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl. In other embodiments, R2 and R3 are independently selected from H, halogen, optionally substituted alkyl, and optionally substituted alkenyl. In other embodiments, R2 and R3 are independently selected from H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C1-C6 alkoxy, and optionally substituted C2-C6 alkenyloxy. In other embodiments, R2 and R3 are independently selected from H, halogen, and C1-C6 alkyl.

[0102] In some embodiments, A is part of equation (II): [ka] During the ceremony, [ka] This represents a bond to D or to L2; R2 and R3 are linked together to form a heterocycline, or heteroaryl, which may be substituted; R4 and R5 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R4 and R5 are linked together to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0103] In some embodiments, R2 and R3 are linked to form an optional heteroaryl that forms a conjugated π system with the phenyl moiety.

[0104] In some embodiments, R4 and R5 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl. In other embodiments, R4 and R5 are independently selected from H, halogen, optionally substituted alkyl, and optionally substituted alkenyl. In other embodiments, R4 and R5 are independently selected from H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C1-C6 alkoxy, and optionally substituted C2-C6 alkenyloxy. In other embodiments, R4 and R5 are independently selected from H, halogen, and C1-C6 alkyl.

[0105] In some embodiments, R4 and R5 are linked to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In other embodiments, R4 and R5 are linked to form an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R4 and R5 are linked to form an optionally substituted aryl or optionally substituted heteroaryl. In some embodiments, R4 and R5 are linked to form an optionally substituted heteroaryl that forms a conjugated π system with the phenyl moiety.

[0106] In some embodiments, A is [ka] Herein, R4 and R5 are as disclosed herein.

[0107] In some embodiments, A is [ka] Herein, R4 and R5 are as disclosed herein.

[0108] In some embodiments, A is [ka] That is the case.

[0109] In some embodiments, n is an integer selected from 1 to 4, 1 to 3, 1 to 2, 2 to 4, 3 to 4, or 3 to 5.

[0110] In some embodiments, D is an electron-donating moiety. An electron donor is a chemical entity that donates electrons to be transferred to another moiety or compound. In some embodiments, D has an electron-donating substituent.

[0111] In some embodiments, D is independently selected from an optionally substituted alkenylene, an optionally substituted arylene, or an optionally substituted heteroarylene. In some embodiments, D is independently selected from an optionally substituted alkenylene, an arylene, or an optionally substituted heteroarylene. In other embodiments, the arylene is phenylene. In other embodiments, the optionally substituted heteroarylene is an optionally substituted monocyclic heteroarylene or an optionally substituted condensed heteroarylene. The heteroarylene may be a 5-membered heteroarylene or a 6-membered heteroarylene. The heteroarylene may be a condensed heteroarylene. In some embodiments, the heteroarylene is a condensed 5,5-membered heteroarylene, a condensed 5,6-membered heteroarylene, a condensed 6,6-membered heteroarylene, a condensed 5,5,6-membered heteroarylene, a condensed 5,6,6-membered heteroarylene, a condensed 6,6,6-membered heteroarylene, a condensed 5,5,6,6-membered heteroarylene, a condensed 5,6,6,6-membered heteroarylene, or a condensed 6,6,6,6-membered heteroarylene.

[0112] In some embodiments, the optional substituent of D is selected from halogens, cyanos, optionally substituted alkyls, optionally substituted alkenyls, optionally substituted alkynyls, optionally substituted alkoxys, optionally substituted alkenyloxys, and optionally substituted alkynyloxys. In other embodiments, the optional substituent of D is selected from halogens, cyanos, alkyls, alkenyls, alkoxys, and alkenyloxys.

[0113] In some embodiments, D is [ka] This is the part selected from, in the formula, [ka] This represents a connection to A or to L2; Each X1 is independently selected from C, O, N, S, and Se; Each X2, if present, is independently selected from C, O, N, S, and Se; If X2 exists, then at least one of X1 and X2 is O, N, or S; R is independently selected from H, halo, cyano, and optionally substituted alkyl groups.

[0114] In some embodiments, D is a substituted five-membered heteroarylene.

[0115] In some embodiments, D is part of equation (III): [ka] In the formula, Y is NR, O, S, or Se; R6 and R7 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R6 and R7 are linked to form optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; R is selected from H, halo, cyano, and optionally substituted alkyl groups.

[0116] In some embodiments, R6 and R7 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, or optionally substituted alkenyloxy. In other embodiments, R6 and R7 are independently selected from H, halogen, optionally substituted alkyl, or optionally substituted alkoxy. In other embodiments, R6 and R7 are independently selected from H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C1-C6 alkoxy, or optionally substituted C2-C6 alkenyloxy. In other embodiments, R6 and R7 are independently selected from H, halogen, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 alkoxy. In other embodiments, R6 and R7 are independently selected from H, halogen, or optionally substituted C1-C6 alkyl.

[0117] In some embodiments, R6 and R7 are linked to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In other embodiments, R6 and R7 are linked to form an optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0118] In some embodiments, D is [ka] Herein, R6 and R7 are as disclosed herein.

[0119] In some embodiments, D is [ka] That is the case.

[0120] In some embodiments, m is an integer selected from 1 to 4, 1 to 3, 1 to 2, 2 to 4, 3 to 4, or 3 to 5.

[0121] In some embodiments, n and m are at least 3 in total. In other embodiments, n and m are at least 4 or 5 in total.

[0122] In some embodiments, each R1 is independently selected from an optionally substituted alkyl, optionally substituted alkoxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted oxyacyloxy, optionally substituted thio, or optionally substituted phosphoryl. In other embodiments, R1 is an optionally substituted alkoxy, optionally substituted oxyacyl, or optionally substituted amino. In yet another embodiment, R1 is an optionally substituted polyethoxy with monomer units of 3 to 10. In yet another embodiment, the chain length of R1 is approximately 3 to approximately 10. In yet another embodiment, R1 is an optionally substituted C3-C 10 Alkoxy, possibly substituted C3-C 10 Alkylamino, possibly substituted C3-C 10 Dialkylamino, optionally substituted C3-C 10 It is an alkyloxyacyl or an optionally substituted polyethoxy. In some embodiments, R1 is independently selected from optionally substituted alkyls and optionally substituted alkoxys. In some embodiments, R1 is independently selected from alkyls and alkoxys, and may be substituted with aminos or alkylaminos, respectively.

[0123] In some embodiments, the optional substituent of R1 is independently selected from oxy, oxyacyl, acyl, amino, phosphoryl, thiol, alkyl, alkenyl, alkynyl, oxyalkyl, alkylacyloxy, sulfonyl, chlorate, or its charged species. In some embodiments, the optional substituent of R1 is independently selected from hydroxyl, carboxyl, phosphate, amino, alkylamino, dialkylamino, chlorate, sulfate, acetate, or its charged species. In some embodiments, the optional substituent of R1 is a tertiary amino. The tertiary amino is neutralizable with a counterion that may be a halide.

[0124] In other embodiments, the optionally substituted substituent of R1 is a hydrophilic moiety. In other embodiments, the optionally substituted substituent of R1 is a charged moiety. Examples of hydrophilic and / or charged moieties include trialkylammonium halides. For example, the charged moiety may be trimethylammonium iodide. In this embodiment, R1 is terminated with trimethylammonium, thereby conferring a positive charge to R1 (e.g., alkyl) upon substitution. Other cationic charged groups include, but are not limited to, pyridinium, pyrrolidinium, imidazolium, guanidium, sulfonium, thiouronium, and phosphonium. Other anionic charged groups include, but are not limited to, chlorates, sulfates, phosphates, acetates, carboxyls, and hydroxides. The hydrophilic and / or charged moiety may be in a zwitterionic form containing both cationic and anionic charged groups via covalent bonds. Excess charge can be neutralized by an acceptable cation or anion.

[0125] Basic nitrogen-containing groups can be quaternized by halogenated lower alkyl groups, such as chloride, bromide, and methyl, ethyl, propyl, and butyl iodides; and dialkyl sulfates, such as dimethyl and diethyl sulfates. Examples of optional substituents for R1 are: [ka] It can be selected from the following.

[0126] For example, to achieve the functionality of "Gram" selectivity, the compounds of the present invention may contain charged ammonium groups. To achieve a transmembrane structure, one side is required to cross a hydrophobic bilayer core. When this is achieved, the charged portion "retains" the compound throughout the bilayer, preventing it from easily detaching. This allows Gram-positive bacterial cells to be visualized over a long period of time.

[0127] To balance hydrophilicity and hydrophobicity so as to facilitate insertion of the compound of Formula (I) into the lipid bilayer, at least one side chain should be present at each end of the backbone. In this regard, in some embodiments, q is an integer of 1 to 4. In other embodiments, q is an integer of 1 to 3. In some embodiments, q' is an integer of 1 to 4. In other embodiments, q' is an integer of 1 to 3. In this regard, the compound of Formula (I) or sub-formulae (Ia to Ig) has a total of at least 2 R1 groups, at least 3 R1 groups, at least 4 R1 groups, at least 5 R1 groups, or at least 6 R1 groups present therein.

[0128] In order for the compound of Formula (I) to maintain its linear configuration, R1 is preferentially located at the meta-position and / or para-position of the terminal phenyl group. In some embodiments, R1 is present at the meta-position and para-position of the terminal phenyl group. In other embodiments, R1 is present at the meta-position or para-position of the terminal phenyl group.

[0129] In some embodiments, the compound of Formula (I) is a compound of Formula (Ia): [Chemical Formula] wherein L1, A, D, R1, n, m, q, and q' are as disclosed herein.

[0130] In some embodiments, the compound of Formula (I) is a compound of Formula (Ib): [Chemical Formula] wherein L1, A, D, R1, n, m, q, and q' are as disclosed herein.

[0131] In some embodiments, the compound of Formula (I) is a compound of Formula (Ib), wherein A is a moiety of Formula (II): [Chemical Formula] wherein [ka] This represents a bond to D or to L2; R2 and R3 are linked together to form a heterocycline, or heteroaryl, which may be substituted; R4 and R5 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R4 and R5 are linked to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; D is part of equation (III): [ka] In the formula, Y is NR, O, or S; R6 and R7 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R6 and R7 are linked to form optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; R is selected from H, halo, cyano, and optionally substituted alkyl groups.

[0132] In some embodiments, the compound of formula (I) is the compound of formula (Ib), where, A is [ka] In the formula, R4 and R5 are as disclosed herein; D is [ka] Herein, R6 and R7 are as disclosed herein.

[0133] In some embodiments, the compound of formula (I) is the compound of formula (Ic): [ka] Each R1 is independently selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aminoacyloxy, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted thio, or optionally substituted phosphoryl; R2 and R3 are linked together to form a heterocycline, or heteroaryl, which may be substituted; R4 and R5 are independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, or optionally substituted alkynyloxy; or R4 and R5 are linked to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; R6 and R7 are each independently selected from H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy; or R6 and R7 are linked to form an optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted cycloalkynyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each R8 is independently selected from halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; Y is NR, O, or S; each p is an integer independently selected from 0 to 4; q is an integer selected from 1 to 5; q' is an integer selected from 1 to 5.

[0134] In some embodiments, the compound of formula (I) is a compound of formula (Id):

Chemical Formula

[0135] In some embodiments, the compound of formula (I) is a compound of formula (Ie):

Chemical Formula

[0136] In some embodiments, the compound of formula (I) is a compound of formula (If):

Chemical Formula

[0137] In some embodiments, each R8 is independently selected from halogens, cyanos, optionally substituted alkyls, optionally substituted alkenyls, or optionally substituted alkynyls. In other embodiments, each R8 is independently selected from halogens, cyanos, or optionally substituted alkyls. In other embodiments, each R8 is independently selected from halogens, cyanos, methyls, ethyls, or propyls.

[0138] In some embodiments, each R8 is independently selected from H or an optionally substituted C1-C5 alkyl group. In other embodiments, each R8 is independently selected from H or an optionally substituted C1-C5 alkyl group. In other embodiments, each R8 is independently selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, sec-butyl, isobutyl, or tertbutyl.

[0139] In some embodiments, each R9 is an optionally substituted alkyl group. In other embodiments, each R9 is a C1-C5 alkyl group. In other embodiments, each R9 is independently selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, sec-butyl, isobutyl, or tertbutyl.

[0140] In some embodiments, the compound of formula (I), or a salt or solvate thereof, [ka] Selected from.

[0141] In some embodiments, the compound of formula (I) is a salt thereof. The salt form may be a protonated salt, or it may be produced by alkylating the compound of formula (I) with a carbon halide. For example, alkyl halides (e.g., CH3Br or CH3I) may be used. In some embodiments, the compound of formula (I), or its salt or solvate, is a quaternary ammonium salt. In this regard, if R1 is an amino which may be substituted, each R1 may be alkylated such that it exhibits at least a positive charge at its respective terminus.

[0142] For example, the quaternary ammonium salt of the compound of formula (I) is [ka] It is possible.

[0143] The compounds of the present invention may be in the form of free compounds, solvates (e.g., hydrates), or crystalline forms, and any form is intended to be within the scope of the present invention. Methods of solvation are generally known in the art.

[0144] The compound of the present invention can be provided as a solid or a solution. For example, the compound can be provided as a freeze-dried powder.

[0145] The compounds of the present invention can be provided as compositions. A composition may contain the compound as a single entity in a polar medium. As used herein, “polar medium” includes polar protic solvents and polar aprotic solvents. Polar solvents have a large dipole moment or partial charge and contain bonds between atoms with very varying electronegativity, such as oxygen and hydrogen. Protic solvents have OH or NH bonds. These bonds enable participation in hydrogen bonding. Furthermore, these OH or NH bonds are compatible with protons (H +A non-protic solvent may have hydrogen somewhere in it, but lacks an OH or NH bond and therefore cannot form hydrogen bonds with itself. Examples of polar solvents include, but are not limited to, dichloromethane, tetrahydrofuran, ethyl acetate, acetone, N,N-dimethylformamide, acetonitrile, dimethyl sulfoxide, ammonia, butanol, propanol, ethanol, methanol, acetic acid, and water. Solvent mixtures in which the main component is a polar solvent are also included in this definition. For example, a water-based solvent or solvent system may contain dissolved ions, salts, and molecules such as amino acids, proteins, sugars, and phospholipids. These salts may include, but are not limited to, sodium chloride, potassium chloride, ammonium acetate, magnesium acetate, magnesium chloride, magnesium sulfate, potassium acetate, potassium chloride, sodium acetate, sodium citrate, zinc chloride, sodium HEPES, calcium chloride, ferric nitrate, sodium bicarbonate, potassium phosphate, and sodium phosphate. Therefore, biological fluids, physiological solutions, and culture media are also included in this definition.

[0146] In some embodiments, the composition comprises a compound of formula (I) or subformulas (Ia-Ig) and a polar medium. For example, in another embodiment, when the MIC value is 256 μM, the composition comprises a compound of formula (I) or subformulas (Ia-Ig) and a polar medium, and the final concentration of the compound of formula (I) or subformulas (Ia-Ig) is about 130 μM. In other embodiments, the concentrations are about 10 μM, about 20 μM, about 30 μM, about 40 μM, about 50 μM, about 100 μM, about 150 μM, about 200 μM, about 250 μM, about 300 μM, about 350 μM, or about 400 μM. In other embodiments, the concentration is 10 μM or less, 20 μM or less, 30 μM or less, 40 μM or less, 50 μM or less, 100 μM or less, 150 μM or less, 200 μM or less, 250 μM or less, 300 μM or less, 350 μM or less, or 400 μM or less.

[0147] Alternatively, the compound may be provided as a kit. The kit may include the compound and a polar medium. The compound and the polar medium may be in separate containers or as separately packaged components so that they are mixed before use. Alternatively, the kit may include a composition of the compound in a first polar medium and a second medium separately, as components housed in separate containers. The kit may further include another dye for staining other components of bacterial cells. For example, the kit may further include FM 4-64. The kit may further include excipients. The excipients may act to further stabilize the compound and / or to reduce background noise by further quenching its fluorescence before it can penetrate the bacterial cell membrane.

[0148] Flow cytometry is a technique for studying living cells, bacterial cells, and extracellular vesicles (e.g., lipid vesicles, exosomes), and is used in laboratories in both academic and industrial facilities. These biological samples are characterized by the essential presence of lipid bilayers (membranes), and COEs are designed to maintain high affinity with lipid bilayers (membranes). Therefore, due to the physicochemical and photoelectronic properties of the compound of the present invention when bound within lipid bilayers, this compound can be used as a dye for flow cytometry applications.

[0149] The compounds of the present invention are suitable for use as fluorescent probes. For example, the skeleton of the present compound can be adjusted to have a certain length (about 3.4 nm), and further to have a topology suitable for specific membrane insertion. By extending the length of the skeleton in this way, it can correspond to the thickness of the lipid bilayer (about 4 nm), and thus the toxicity to cells, as well as bacteria such as Escherichia coli (E.coli) and Staphylococcus aureus (S.aureus) can be extremely low (MIC value exceeds 256 μM). In this regard, the present compounds can be used as dyes in biological systems without reducing cell viability. Second, to achieve sufficient solubility in aqueous media, 6 positively charged side chains can be included in the present compound as terminal groups. It has been found that as the length of the hydrophobic conjugated core increases, the number of charged side chains must be balanced to endow the COE compounds with good water solubility. An unfavorable hydrophilic / hydrophobic profile and strong aggregation tendency will affect effective membrane insertion and affect fluorescence stability (fluorescence quenching is more likely to occur). For example, a 5-benzene ring oligophenylene vinylene skeleton with 4 positively charged side chains at both ends shows some aggregation tendency. At a concentration of 1 mg mL -1 , the aqueous solution will be visibly turbid to the naked eye. This suggests that many aggregates are present in the incompletely dissolved suspension. When modified with 6 charged side chains, the COE compound exhibits excellent solubility in aqueous solution (>50 mg mL -1 ). The feature that the aqueous solution of the COE compound is transparent and homogeneous enhances its practical value, especially when it is required to be stored at a high concentration before dilution and use. Third, it is expected that the extension of the skeleton of the COE compound will promote the improvement of membrane stability, while the increase of hydrophilic groups is expected to increase water solubility. In addition, it was envisioned that combining these physical features would increase both hydrophobic and electrostatic interactions, thereby facilitating insertion within the bilayer. Therefore, when used as a membrane labeling dye, the COE compound can be stably incorporated into the lipid bilayer by a strong binding force for long-term staining.

[0150] Figure 16 shows the change in fluorescence emission when the A and D units of this compound are varied. Referring to COE-Quin, in which the alternately arranged phenyl moieties exhibit weak electron-accepting and electron-donating properties, the fluorescence excitation, and therefore the emission, can be calibrated to a specific wavelength by adjusting the electron-accepting and electron-donating properties of the A and D units. Furthermore, the selection of these units narrows the FWHM, thus improving specificity.

[0151] Therefore, the present invention also provides a compound of formula (Ig), or a salt or solvate thereof: [ka] During the ceremony, Each R1 is independently selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aminoacyloxy, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted thio, or optionally substituted phosphoryl; q is an integer selected from 1 to 5; q' is an integer selected from 1 to 5; r is an integer selected from 1 to 5.

[0152] These compounds can be applied to stain bacterial cells, mammalian cells (including, but not limited to, A549 cancer cells and erythrocytes), and exosomes (especially unbound exosomes).

[0153] Therefore, the present invention relates to a method for labeling cells and / or lipid vesicles, a) A method is provided comprising the step of incubating a compound of formula (I), subformulas (Ia-Ig), or a salt or solvate thereof with cells and / or lipid vesicles.

[0154] The cells may be mammalian cells or bacterial cells. In some embodiments, the bacterial cells may be Gram-positive or Gram-negative. In other embodiments, the Gram-negative or Gram-positive bacterial cells may be selected from the group consisting of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Shewanella oneidensis, Bacillus megatherium, or combinations thereof. The mammalian cells may be from a cell line or from a sample obtained from the subject.

[0155] In some embodiments, the bacterial cell sample is a sample of planktonic bacterial cells.

[0156] As used herein, “floating bacterial cells” refers to free-flowing bacterial cells in a suspended state. This is in contrast to a fixed state (or biofilm), in which structured aggregates of bacterial cells are encapsulated in a self-generating polymer matrix and attached to an inert or biological surface. In this regard, floating bacteria are bacteria that grow freely and constitute populations that grow in test tubes and flask cultures in the laboratory.

[0157] Lipid vesicles are structures inside or outside cells that consist of fluid or cytoplasm encapsulated in a lipid bilayer. Vesicles form spontaneously during the processes of secretion (exocytosis), uptake (endocytosis), and transport of substances within the plasma membrane. Alternatively, they can be artificially prepared, in which case they are called liposomes. Monolayer lipid vesicles have one phospholipid bilayer, while multilayer lipid vesicles have two or more bilayers. Vesicles can also fuse with other organelles within the cell. Vesicles released from a cell are extracellular vesicles. For example, lipid vesicles can be exosomes. Exosomes are membrane-bound extracellular vesicles produced in the endosomal compartment of most eukaryotic cells. These lipid vesicles fall within this range.

[0158] In some embodiments, the lipid vesicles are extracellular vesicles. In other embodiments, the lipid vesicles are exosomes.

[0159] In some embodiments, this method A step of contacting a sample of cells and / or lipid vesicles with a compound of formula (I), subformulas (Ia-Ig), or their salts or solvates under predetermined conditions. Includes.

[0160] In some embodiments, cells and / or lipid vesicles are incubated with compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates at a concentration of the compound below its MIC value. In other embodiments, cells and / or lipid vesicles are incubated with compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates at a concentration of the compound below half its MIC value. In some embodiments, cells and / or lipid vesicles are incubated with compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates at a concentration of the compound below one-third its MIC value. The minimum inhibitory concentration (MIC) is the lowest concentration of a chemical substance that prevents the visible growth of one or more bacteria. The MIC is microorganism- and chemical substance-dependent. The MIC of a compound can be determined by incubating cells with various concentrations of the compound in liquid medium or on a solid growth medium (e.g., agar) plate and identifying the compound concentration at which bacteria did not grow and the next lowest dose at which bacterial growth was enabled. This information can also be derived from a turbidity plot against compound concentration. Other methods are available to determine the MIC value, such as using the Etest test or the Kirby-Bauer test.

[0161] In some embodiments, the MIC value is greater than approximately 1 μM. In other embodiments, the MIC value is greater than approximately 5 μM, greater than approximately 10 μM, greater than approximately 20 μM, greater than approximately 30 μM, greater than approximately 40 μM, greater than approximately 50 μM, greater than approximately 60 μM, greater than approximately 70 μM, greater than approximately 80 μM, greater than approximately 90 μM, greater than approximately 100 μM, greater than approximately 150 μM, greater than approximately 200 μM, greater than approximately 250 μM, greater than approximately 300 μM, greater than approximately 350 μM, greater than approximately 400 μM, or greater than approximately 500 μM.

[0162] In some embodiments, compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates are realized at concentrations of approximately 1 nM to approximately 100 μM. In other embodiments, concentrations are approximately 1 nM to approximately 90 μM, approximately 1 nM to approximately 80 μM, approximately 1 nM to approximately 70 μM, approximately 1 nM to approximately 60 μM, approximately 1 nM to approximately 50 μM, approximately 1 nM to approximately 40 μM, approximately 1 nM to approximately 30 μM, approximately 1 nM to approximately 20 μM, approximately 1 nM to approximately 10 μM, approximately 1 nM to approximately 5 μM, approximately 1 nM to approximately 1 μM, and approximately 1 nM ~ about 900nM, about 1nM - about 800nM, about 1nM - about 700nM, about 1nM - about 600nM, about 1nM - about 500nM, about 1nM - about 400 nM, about 1 nM to about 300 nM, about 1 nM to about 200 nM, about 1 nM to about 100 nM, about 1 nM to about 50 nM, or about 1 nM to about 20 nM.

[0163] In some embodiments, compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates are incubated with cells and / or lipid vesicles at approximately 5°C to approximately 50°C. In other embodiments, the temperature is approximately 5°C to approximately 45°C, approximately 5°C to approximately 40°C, approximately 5°C to approximately 35°C, approximately 10°C to approximately 35°C, approximately 15°C to approximately 35°C, or approximately 15°C to approximately 30°C. In other embodiments, the temperature is room temperature or ambient temperature.

[0164] In some embodiments, compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates are incubated with cells and / or lipid vesicles for about 5 minutes to about 120 minutes. In other embodiments, the incubation period is about 5 minutes to about 110 minutes, about 5 minutes to about 100 minutes, about 5 minutes to about 90 minutes, about 5 minutes to about 80 minutes, about 5 minutes to about 70 minutes, about 5 minutes to about 60 minutes, about 5 minutes to about 50 minutes, about 5 minutes to about 40 minutes, about 5 minutes to about 30 minutes, about 5 minutes to about 20 minutes, or about 5 minutes to about 10 minutes.

[0165] Compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates, as well as cells and / or lipid vesicles, can be incubated in an aqueous medium.

[0166] As used herein, the term “aqueous medium” means a water-based solvent or solvent system, and a solvent or solvent system primarily composed of water. These solvents may be polar or nonpolar, and / or protic or aprotic. A solvent system means a combination of solvents that produce a single final phase. Examples of both “solvents” and “solvent systems” include, but are not limited to, pentane, cyclopentane, hexane, cyclohexane, benzene, toluene, dioxane, chloroform, diethyl ether, dichloromethane, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide, nitromethane, propylene carbonate, formic acid, butanol, isopropanol, propanol, ethanol, methanol, acetic acid, ethylene glycol, diethylene glycol, or water. A water-based solvent or solvent system may contain dissolved ions, salts, and molecules such as amino acids, proteins, sugars, and phospholipids. These salts may, but are not limited to, sodium chloride, potassium chloride, ammonium acetate, magnesium acetate, magnesium chloride, magnesium sulfate, potassium acetate, potassium chloride, sodium acetate, sodium citrate, zinc chloride, sodium HEPES, calcium chloride, ferric nitrate, sodium bicarbonate, potassium phosphate, and sodium phosphate. Therefore, biological fluids, physiological solutions, and culture media are also included in this definition.

[0167] The present invention also relates to a method for detecting cells and / or lipid vesicles using a fluorescence detector, a) A step of incubating compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates with cells and / or lipid vesicles; and b) The step of passing cells and / or lipid vesicles through a fluorescence detector. This provides a method that includes [something].

[0168] Since compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates emit fluorescence when inserted into the cell membrane or lipid bilayer, fluorescence-based techniques can be used to detect cells and / or lipid vesicles that have incorporated compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates. Examples of fluorescence-based techniques include, but are not limited to, fluorescence microscopy, confocal microscopy, plate readers, fluorophotometers, fluorescence spectroscopy, and flow cytometry (e.g., fluorescence-activated cell sorting).

[0169] In some embodiments, a method for detecting cells and / or lipid vesicles using a flow cytometer is described as follows: a) A step of incubating compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates with cells and / or lipid vesicles; and b) The process of flowing cells and / or lipid vesicles through a flow cytometer. Includes.

[0170] When compounds of formula (I), subformulas (Ia-Ig), or their salts or solvates are incorporated, cells and / or lipid vesicles can be excited by electromagnetic radiation (sources) in the wavelength range of approximately 300 nm to approximately 1000 nm.

[0171] The present invention also relates to a method for detecting cells and / or lipid vesicles using a flow cytometer, a) Equation (IV); [ka] (In the formula, R1 is independently selected from halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted acyl, optionally substituted oxyacyl, optionally substituted acyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aminoacyloxy, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, or optionally substituted thio or optionally substituted phosphoryl; R2 is independently selected from halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; u is an integer selected from 3 to 15; Each s is an integer independently selected from 0 to 4; q is an integer selected from 2 to 5; (q' is an integer selected from 2 to 5) The steps of incubating the compound, or a salt or solvate thereof, with cells and / or lipid vesicles; and b) The process of flowing cells and / or lipid vesicles through a flow cytometer. This provides a method that includes [something].

[0172] In some embodiments, R2 is independently selected from halogens, cyanos, optionally substituted alkyls, optionally substituted alkenyls, or optionally substituted alkynyls. In other embodiments, R2 is independently selected from halogens, cyanos, or optionally substituted alkyls. In other embodiments, R2 is independently selected from halogens, cyanos, methyls, ethyls, or propyls.

[0173] In some embodiments, u is an integer selected from 3 to 14. In other embodiments, u is an integer selected from 3 to 12, 3 to 10, 3 to 9, 3 to 8, 3 to 7, 4 to 7, or 4 to 6. In other embodiments, u is 3, 4, 5, 6, or 7. In some embodiments, u is 4, 5, or 6. In other embodiments, u is 4.

[0174] Examples of the compounds of formula (IV) in the form of salts or solvates are shown below. These examples of compounds of formula (IV) are also within the scope of this disclosure. [ka] TIFF0007948639000066.tif229170TIFF0007948639000067.tif230170TIFF0007948639000068.tif228170 TIFF0007948639000069.tif229170TIFF0007948639000070.tif229170TIFF0007948639000071.tif198170

[0175] Cells can be adherent or suspended. Lipid vesicles can be exosomes (membrane-bound extracellular vesicles produced in the endosomal compartment of eukaryotic cells), synthetic and non-synthetic liposomes, or lipid nanoparticles (spherical vesicles made of ionizable lipids that are positively charged at low pH and neutral at physiological pH). Advantageously, it has been found that after cell membrane insertion with a fluorescent probe, the fluorescent probe can then penetrate subsequent cell populations.

[0176] Cells and / or lipid vesicles are stained after the incubation step with compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates. In some embodiments, incubation periods are approximately 1 minute to 12 days, 1 minute to 10 days, 1 minute to 8 days, 1 minute to 6 days, 1 minute to 5 days, 1 minute to 4 days, 1 minute to 3 days, 1 minute to 2 days, 1 minute to 24 hours, 1 minute to 20 hours, 1 minute to 16 hours, 1 minute to 12 hours, 1 minute to 10 hours, 1 minute to 9 hours, 1 minute to 8 hours, 1 minute to 7 hours, The incubation periods are approximately 1 minute to 6 hours, 5 minutes to 6 hours, 5 minutes to 5.5 hours, 5 minutes to 5 hours, 5 minutes to 4.5 hours, 5 minutes to 4 hours, 5 minutes to 3.5 hours, 5 minutes to 3 hours, 5 minutes to 2.5 hours, 5 minutes to 2 hours, 5 minutes to 1.5 hours, 5 minutes to 1 hour, 5 minutes to 50 minutes, 5 minutes to 40 minutes, 5 minutes to 30 minutes, 5 minutes to 20 minutes, or 5 minutes to 10 minutes. In other embodiments, the incubation period is approximately 10 minutes.

[0177] By controlling the concentration of the compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, a sufficient amount of time for sample analysis can be obtained. In some embodiments, cells and / or lipid vesicles are passed through a flow cytometer within 30 minutes of contact with the compounds of formula (I) and / or formula (IV) of the sample. In other embodiments, the time is within 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 8 days, 10 days, or 12 days. In other embodiments, the time is approximately 30 minutes, approximately 1 hour, approximately 2 hours, approximately 3 hours, approximately 4 hours, approximately 5 hours, approximately 6 hours, approximately 8 hours, approximately 10 hours, approximately 12 hours, approximately 16 hours, approximately 20 hours, approximately 24 hours, approximately 2 days, approximately 3 days, approximately 4 days, approximately 5 days, approximately 6 days, approximately 8 days, approximately 10 days, or approximately 12 days.

[0178] In some embodiments, cells and / or lipid vesicles can be flowed through a flow cytometer without a purification step. This is possible because the free compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, are weakly luminescent and produce relatively low background noise.

[0179] By flowing cells and / or lipid vesicles through a flow cytometer, the cells and / or lipid vesicles can be excited by electromagnetic radiation and subsequently detected by a detector. Therefore, this method may further include a step of exposing the cells and / or lipid vesicles to electromagnetic radiation having a wavelength of less than approximately 2500 nm or less than approximately 1000 nm.

[0180] In some embodiments, compounds of formula (I), subformulas (Ia to Ig), and / or formula (IV), or their salts or solvates, exhibit fluorescence excitation at wavelengths of approximately 300 nm to 1000 nm, or approximately 400 nm to 700 nm. Depending on the combination of D and A, the excitation may be tuned within this wavelength range.

[0181] In some embodiments, compounds of formula (I), subformulas (Ia to Ig), and / or formula (IV), or their salts or solvates, exhibit fluorescence excitation peaks at a full width at half maximum (FWHM) of approximately 10 nm to approximately 200 nm. In other embodiments, the FWHM is approximately 10 nm to approximately 190 nm, approximately 10 nm to approximately 180 nm, approximately 10 nm to approximately 170 nm, approximately 10 nm to approximately 160 nm, approximately 10 nm to approximately 150 nm, approximately 10 nm to approximately 140 nm, approximately 10 nm to approximately 130 nm, approximately 10 nm to approximately 120 nm, approximately 10 nm to approximately 110 nm, or approximately 10 nm to approximately 100 nm. In other embodiments, the FWHM ranges from approximately 20 nm to approximately 200 nm, approximately 30 nm to approximately 200 nm, approximately 40 nm to approximately 200 nm, approximately 50 nm to approximately 200 nm, approximately 60 nm to approximately 200 nm, approximately 70 nm to approximately 200 nm, approximately 80 nm to approximately 200 nm, approximately 90 nm to approximately 200 nm, or approximately 100 nm to approximately 200 nm.

[0182] In some embodiments, compounds of formula (I), subformulas (Ia to Ig), and / or formula (IV), or their salts or solvates, exhibit fluorescence emission at wavelengths of approximately 300 nm to 2000 nm. In other embodiments, the ranges are approximately 300 nm to 1900 nm, approximately 300 nm to 1800 nm, approximately 300 nm to 1700 nm, approximately 300 nm to 1600 nm, or approximately 300 nm to 1500 nm. Depending on the combination of D and A, the excitation may be tuned within this wavelength range.

[0183] In some embodiments, compounds of formula (I), subformulas (Ia to Ig), and / or formula (IV), or their salts or solvates, exhibit fluorescence emission peaks with a full width at half maximum (FWHM) of approximately 10 nm to approximately 200 nm. In other embodiments, the FWHM is approximately 10 nm to approximately 190 nm, approximately 10 nm to approximately 180 nm, approximately 10 nm to approximately 170 nm, approximately 10 nm to approximately 160 nm, approximately 10 nm to approximately 150 nm, approximately 10 nm to approximately 140 nm, approximately 10 nm to approximately 130 nm, approximately 10 nm to approximately 120 nm, approximately 10 nm to approximately 110 nm, or approximately 10 nm to approximately 100 nm. In other embodiments, the FWHM ranges from approximately 20 nm to approximately 200 nm, approximately 30 nm to approximately 200 nm, approximately 40 nm to approximately 200 nm, approximately 50 nm to approximately 200 nm, approximately 60 nm to approximately 200 nm, approximately 70 nm to approximately 200 nm, approximately 80 nm to approximately 200 nm, approximately 90 nm to approximately 200 nm, or approximately 100 nm to approximately 200 nm.

[0184] In some embodiments, when compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates are inserted into the cell membrane and / or lipid membrane, the compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, exhibit a luminescence intensity of approximately 2 to 500 times greater than that of control samples of the compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates. In other embodiments, the luminescence intensity is approximately 10 to 500 times, 20 to 500 times, 30 to 500 times, 40 to 500 times, 50 to 500 times, 60 to 500 times, 70 to 500 times, 80 to 500 times, 90 to 500 times, 100 to 500 times, 100 to 450 times, 150 to 450 times, 200 to 450 times, 250 to 450 times, 300 to 450 times, or 350 to 450 times.

[0185] In an experiment, a control is a group isolated from the rest of the experiment, whose independent variable being tested cannot influence the results. When testing samples of cells and / or lipid vesicles, at least one control sample may contain a compound of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, in an aqueous / water medium. In this respect, the control sample does not contain cells and / or lipid vesicles.

[0186] Advantageously, the photoluminescence of compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, when dissolved in an aqueous medium is low (or very low). However, when partitioned into a lipid bilayer, the photoluminescence of compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, is enhanced. This enhancement of fluorescence is thought to be due to a change in the local environment to a hydrophobic environment (alkyl chains in the lipid bilayer). Fluorescence is the emission of light by a substance that has absorbed light or other electromagnetic radiation. Generally, emitted light has a longer wavelength than absorbed light.

[0187] Advantageously, the compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, are non-toxic (or exhibit low toxicity) and / or stable to excitation, allowing the photoluminescence intensity to be maintained for a certain period under constant excitation. In this regard, when the compound is excited at an appropriate wavelength for imaging, the photoluminescence intensity does not decrease for a certain period of time. This is thought to be due to a conjugated system that dissipates and transfers energy, thereby preventing local heating and decomposition of the compound. In some embodiments, the photoluminescence intensity can be maintained for at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, at least 1.5 hours, at least 2 hours, at least 3 hours, at least 4 hours, at least 6 hours, at least 10 hours, or at least 24 hours.

[0188] Compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, can work in combination with other dyes, such as membrane dyes. For example, the commercially available dye FM4-64 can be added to recognize the type of bacterial envelope in situ in a bacterial mixture. In this regard, a dual dye system capable of recognizing multimicrobial samples is also disclosed. These methods are easy to use, require only simple application of the dye mixture, require no fixation or other pretreatment, and the compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, are stable in aqueous solution and can be used to monitor cells in biological systems.

[0189] Therefore, in one embodiment, the method further includes the step of contacting cells and / or lipid vesicles with another dye. The dye can be used to stain cell membranes, nuclei, DNA, RNA, or other organelles in cells. The dye may be a fluorescent probe, e.g., FM4-64, FM2-10, FM1-43, propidium iodide, SYTO 82, SYTO 83, SYTO 84, SYTO 85, YOYO®-3 iodide, YO-PRO®-3 iodide, BOBO®-3 iodide, ethidium homodimer 1, ethidium homodimer 2, ethidium monoazide, acridine orange, CellMask® plasma membrane stain, or Di-4-ANEPPS.

[0190] The present invention also relates to a flow system for detecting and / or quantifying cells and / or lipid vesicles, a) Compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or salts or solvates thereof, for labeling cells and / or lipid vesicles; b) An entry point for introducing labeled cells and / or lipid vesicles into the flow system; c) Inlet and fluid-communicated detection means for detecting fluorescence emission from labeled cells and / or lipid vesicles; and The present invention provides a flow system that optionally includes d) a counting means for quantifying labeled cells and / or lipid vesicles.

[0191] A flow system could be, for example, a microfluidic chip.

[0192] In some embodiments, the flow system further includes incubation means. The incubation means inserts compounds of formula (I), subformulas (Ia-Ig), and / or formula (IV), or their salts or solvates, into the cell membrane or lipid bilayer.

[0193] In some embodiments, the detection means is a fluorescence detector.

[0194] It will be recognized that many further modifications and substitutions are possible with respect to the various aspects of the embodiments described. Accordingly, the embodiments described are intended to encompass all such modifications, alterations, and variations that fall within the true intent and scope of the appended claims.

[0195] Throughout this specification and the claims, unless otherwise required by context, the term “comprise,” and variations such as “comprises” and “comprising,” shall be understood to imply the inclusion of the integer or process, or group of integers or processes, described, but not the exclusion of any other integer or process, or group of integers or processes.

[0196] No reference in this Specification to any prior publication (or information derived therefrom) or to any publicly known matter constitutes, and should not be construed as, an acknowledgment, or any form of suggestion, that such prior publication (or information derived therefrom) or publicly known matter forms part of the common general knowledge in the field of business to which this Specification relates. [Examples]

[0197] General protocol for the synthesis of the compound of formula (I)

[0198] [ka]

[0199] [ka]

[0200] [ka]

[0201] (E)-1,2,3-Tris((6-bromohexyl)oxy)-5-(4-bromostyryl)benzene (compound 3) Compound 1 (5.69 g, 8.46 mmol), Compound 2 (4.07 g, 13.27 mmol), potassium tert-butoxide (0.99 g, 8.46 mmol), and 100 mL of dry THF were added to a round-bottom flask under the protection of a nitrogen atmosphere. After reacting for 16 hours with stirring at room temperature, the reaction mixture was poured into water and extracted with chloroform. The clear organic phase was dried over Na2SO4, and the organic solvent was removed using a rotary evaporator. The crude product was purified by column chromatography using hexane and dichloromethane as eluents, and the product was obtained as a white solid (6.63 g, 94% yield). 1 H NMR (400 MHz, chloroform-d) δ 7.49 - 7.44 (m, 2H), 7.37 - 7.33 (m, 2H), 6.99 (d, J = 16.2 Hz, 1H), 6.90 (d, J = 16.2 Hz, 1H), 6.70 (s, 2H), 4.06 - 4.00 (m, 4H), 3.99 - 3.95 (m, 2H), 3.49 - 3.39 (m, 6H), 1.96 - 1.71 (m, 12H), 1.60 - 1.47 (m, 12H). 13 C NMR (101 MHz, CDCl3) δ 153.56, 138.68, 136.62, 132.69, 132.12, 129.82, 128.18, 126.95, 121.51, 105.65, 73.58, 69.27, 34.25, 34.12, 33.20, 33.07, 30.48, 29.61, 28.44, 28.27, 25.70, 25.68.

[0202] (E)-2-(4-(3,4,5-Tris((6-bromohexyl)oxy)styryl)phenyl)thiophene (compound 5) Compound 3 (4.44 g, 5.58 mmol), Compound 4 (4.16 g, 11.15 mmol), and Pd(PPh3)2Cl2 (157 mg, 0.223 mmol) were added to a round-bottom flask under the protection of a nitrogen atmosphere. After purging with nitrogen, 50 mL of dry toluene was added to the reaction mixture, and the mixture was then heated at 120°C for 16 hours with stirring. After cooling to room temperature, the reaction mixture was poured into water and extracted with chloroform. The organic phase was dried over Na2SO4, and the organic solvent was removed using a rotary evaporator. The crude product was purified by silica gel column chromatography using hexane and dichloromethane as eluents, and the product was obtained as a bright yellow solid (4.02 g, 90% yield). 1 H NMR (400 MHz, chloroform-d) δ 7.63 - 7.58 (m, 2H), 7.52 - 7.48 (m, 2H), 7.33 (dd, J = 3.6, 1.2 Hz, 1H), 7.28 (dd, J = 5.1, 1.1 Hz, 1H), 7.09 (dd, J = 5.1, 3.6 Hz, 1H), 7.03 (d, J = 16.2 Hz, 1H), 6.97 (d, J = 16.3 Hz, 1H), 6.72 (s, 2H), 4.09 - 3.95 (m, 6H), 3.49 - 3.39 (m, 6H), 1.97 - 1.73 (m, 12H), 1.62 - 1.48 (m, 12H). 13 C NMR (101 MHz, CDCl3) δ 153.55, 144.48, 138.57, 136.85, 133.85, 133.03, 129.11, 128.44, 127.64, 127.20, 126.45, 125.15, 123.34, 105.65, 73.59, 69.29, 34.24, 34.11, 33.21, 33.09, 30.50, 29.64, 28.46, 28.28, 25.72, 25.70.

[0203] (E)-Trimethyl(5-(4-(3,4,5-Tris((6-bromohexyl)oxy)styryl)phenyl)thiophen-2-yl)stannane(compound 6) Compound 5 (2.88 g, 3.60 mmol) and 40 mL of dry THF were added to a flask under nitrogen protection. The mixture was cooled to -80°C using a cryogenic reaction bath. Next, 3.6 mL of cyclohexane solution of n-butyllithium (2 M, 7.2 mmol) was added dropwise to the reaction mixture. After stirring at -80°C for 2 hours, 14.4 mL of hexane solution of trimethyltin chloride (1 M, 14.4 mmol) was added, and the reaction mixture was then raised to room temperature. After stirring overnight (approximately 16 hours) at room temperature, the reaction mixture was poured into water and extracted with hexane. The organic phase was washed four times with water and then dried over Na₂SO₄. After removing the solvent using a rotary evaporator and vacuum pump, the crude product was obtained as a colorless oil. This was used in the next reaction without further purification (3.34, yield 96%). 1 H NMR (400 MHz, chloroform-d) δ 7.63 - 7.58 (m, 2H), 7.52 - 7.47 (m, 2H), 7.44 (d, J = 3.3 Hz, 1H), 7.17 (d, J = 3.3 Hz, 1H), 7.05 - 6.93 (m, 2H), 6.72 (s, 2H), 4.09 - 3.92 (m, 6H), 3.51 - 3.36 (m, 6H), 1.97 - 1.71 (m, 12H), 1.62 - 1.47 (m, 12H), 0.40 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 153.54, 150.19, 138.51, 138.18, 136.61, 136.59, 133.97, 133.09, 128.92, 127.74, 127.17, 126.47, 124.59, 105.60, 73.59, 69.27, 34.25, 34.12, 33.22, 33.09, 30.50, 29.64, 28.46, 28.29, 25.72, 25.70, -7.87.

[0204] 4,7-Bis(5-(4-((E)-3,4,5-Tris((6-bromohexyl)oxy)styryl)phenyl)thiophen-2-yl)benzo[c][1,2,5]thiadiazole (compound 8) Compound 6 (2.76 g, 2.87 mmol), Compound 7 (281 mg, 0.88 mmol), and Pd(PPh3)2Cl2 (27 mg, 0.038 mmol) were added to a round-bottom flask under the protection of a nitrogen atmosphere. After purging with nitrogen, 10 mL of dry toluene was added to the reaction mixture, and the mixture was then heated at 120°C for 16 hours with stirring. After cooling to room temperature, the reaction mixture was poured into water and extracted with chloroform. The organic phase was dried over Na2SO4, and the organic solvent was removed using a rotary evaporator. The crude product was purified by silica gel column chromatography using hexane and dichloromethane as eluents. The product was dissolved in chloroform, precipitated with methanol, the precipitate was filtered, and washed with methanol. After drying under reduced pressure, the product was obtained as a deep red solid (1.29 g, yield 78%). 1 H NMR (500 MHz, chloroform-d) δ 8.12 (d, J = 3.9 Hz, 2H), 7.89 (s, 2H), 7.69 (d, J = 8.4 Hz, 4H), 7.53 (d, J = 8.5 Hz, 4H), 7.43 (d, J = 3.8 Hz, 2H), 7.05 (d, J = 16.2 Hz, 2H), 6.99 (d, J = 16.2 Hz, 2H), 6.73 (s, 4H), 4.08 - 4.02 (m, 8H), 4.01 - 3.96 (m, 4H), 3.47 - 3.40 (m, 12H), 1.96 - 1.74 (m, 24H), 1.60 - 1.47 (m, 24H). 13 C NMR (126 MHz, CDCl3) δ 153.55, 152.90, 145.65, 138.96, 138.57, 137.22, 133.48, 132.96, 129.31, 129.03, 127.54, 127.26, 126.30, 126.06, 125.64, 124.36, 105.60, 73.60, 69.26, 34.28, 34.15, 33.21, 33.09, 30.50, 29.64, 28.46, 28.29, 25.72, 25.71.

[0205] Compound COE-BT Compound 8 (557 mg, 0.322 mmol) and chloroform (40 mL) were added to a single-necked round-bottom flask. After dissolving compound 8, 5 mL of trimethylamine THF solution (2 M) was added to the reaction mixture and the mixture was stirred at 55°C for 16 hours. After the reaction, the crude product precipitated and adhered to the bottom of the flask. The relatively pale solution was poured out, and the solid precipitate was gently rinsed five times with chloroform. Next, the solid precipitate was dissolved with 40 mL of methanol. 5 mL of trimethylamine methanol solution (3.2 M) was added to the reaction mixture and the mixture was stirred at 55°C for a further 16 hours. The solvent was removed by rotary evaporation, and the solid was dried under reduced pressure. The final product was obtained as a deep red solid (605 mg, 90% yield). 1 H NMR (500 MHz, DMSO-d6) δ 8.29 - 8.18 (m, 4H), 7.81 (d, J = 8.0 Hz, 4H), 7.75 (d, J = 3.9 Hz, 2H), 7.68 (d, J = 8.2 Hz, 4H), 7.27 (s, 4H), 6.96 (s, 4H), 4.12 - 4.00 (m, 8H), 3.95 - 3.87 (m, 4H), 3.37 - 3.27 (m, 12H), 3.09 (s, 54H), 1.84 - 1.62 (m, 24H), 1.58 - 1.47 (m, 12H), 1.42 - 1.28 (m, 12H). 13 C NMR (126 MHz, DMSO) δ 153.57, 152.56, 145.89, 138.53, 138.02, 137.88, 133.42, 133.28, 129.93, 129.76, 128.01, 127.88, 126.56, 126.49, 125.68, 125.60, 106.00, 73.27, 69.11, 66.13, 60.82, 53.09, 30.40, 29.56, 26.54, 26.42, 26.02, 25.97, 23.01.

[0206] compound 10 Compound 6 (2.54 g, 2.64 mmol), Compound 9 (0.31 g, 0.88 mmol), and Pd(PPh3)2Cl2 (25 mg, 0.035 mmol) were added to a round-bottom flask under the protection of a nitrogen atmosphere. After purging with nitrogen, 10 mL of dry toluene was added to the reaction mixture, and the mixture was then heated at 120°C for 16 hours with stirring. After cooling to room temperature, the reaction mixture was poured into water and extracted with chloroform. The organic phase was dried over Na2SO4, and the organic solvent was removed using a rotary evaporator. The crude product was purified by silica gel column chromatography using hexane and dichloromethane as eluents. The product was dissolved in chloroform, precipitated using methanol, the precipitate was filtered, and washed with methanol. After drying under reduced pressure, the product was obtained as a brown solid (0.69 g, yield 44%). 1 H NMR (500 MHz, chloroform-d) δ 8.91 (d, J = 4.1 Hz, 2H), 7.71 (d, J = 8.0 Hz, 4H), 7.49 (d, J = 8.5 Hz, 4H), 7.46 (d, J = 4.2 Hz, 2H), 7.03 (d, J = 16.2 Hz, 2H), 6.96 (d, J = 16.1 Hz, 2H), 6.72 (s, 4H), 4.11 - 3.94 (m, 12H), 3.51 - 3.39 (m, 12H), 1.97 - 1.73 (m, 24H), 1.63 - 1.45 (m, 24H). 13 C NMR (126 MHz, CDCl3) δ 153.56, 151.49, 149.12, 138.58, 137.90, 137.43, 134.40, 133.48, 132.94, 129.36, 127.50, 127.23, 126.32, 124.54, 113.50, 105.58, 73.61, 69.26, 34.29, 34.17, 33.22, 33.11, 30.53, 29.66, 28.48, 28.32, 25.74, 25.72.

[0207] Compound COE-BBT Compound 10 (196 mg, 0.110 mmol) and chloroform (20 mL) were added to a single-necked round-bottom flask. After dissolving compound 10, 2 mL of trimethylamine THF solution (2 M) was added to the reaction mixture and the mixture was stirred at 55°C for 16 hours. After the reaction, the crude product precipitated and adhered to the bottom of the flask. The relatively pale solution was poured out, and the solid precipitate was gently rinsed five times with chloroform. Next, the solid precipitate was dissolved with 20 mL of methanol. 2 mL of trimethylamine methanol solution (3.2 M) was added to the reaction mixture and the mixture was stirred at 55°C for a further 16 hours. The solvent was removed by rotary evaporation, and the solid was dried under reduced pressure. The final product was obtained as a brown solid (219 mg, 93% yield). 1 H NMR (400 MHz, DMSO-d6) δ 9.13 - 9.04 (m, 2H), 7.97 - 7.83 (m, 6H), 7.77 - 7.66 (m, 4H), 7.29 (br, 4H), 6.97 (br, 4H), 4.12 - 3.99 (m, 8H), 3.95 - 3.85 (m, 4H), 3.39 - 3.23 (m, 12H), 3.09 (s, 54H), 1.86 - 1.63 (m, 24H), 1.59 - 1.47 (m, 12H), 1.43 - 1.28 (m, 12H). 13 ¹³C NMR (126 MHz, DMSO) δ 153.57, 151.50, 148.78, 138.24, 138.06, 137.70, 134.93, 133.40, 133.29, 130.12, 128.08, 127.89, 126.72, 125.98, 113.24, 106.01, 73.27, 69.10, 66.11, 58.48, 55.32, 55.29, 55.26, 53.07, 30.41, 29.56, 26.55, 26.43, 26.02, 25.98, 23.00.

[0208] compound 12 The synthesis and purification procedures were the same as for compound 5. The reactant tributyl(thiophen-2-yl) stannan (compound 4) was replaced with (3,4-ethylenedioxythien-2-yl)trimethylstannan (compound 11), but the supply ratio was kept the same. The product was obtained as a colorless oil (5.49 g, yield 86%). 1 H NMR (500 MHz, chloroform-d) δ 7.70 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.00 (d, J = 16.2 Hz, 1H), 6.96 (d, J = 16.2 Hz, 1H), 6.72 (s, 2H), 6.31 (s, 1H), 4.36 - 4.31 (m, 2H), 4.29 - 4.23 (m, 2H), 4.08 - 4.01 (m, 4H), 3.99 - 3.94 (m, 2H), 3.48 - 3.39 (m, 6H), 1.96 - 1.72 (m, 12H), 1.62 - 1.46 (m, 12H). 13 C NMR (126 MHz, CDCl3) δ 153.50, 142.61, 138.62, 138.36, 135.80, 133.13, 132.72, 128.67, 127.87, 126.93, 126.42, 117.68, 105.48, 98.04, 73.57, 69.22, 65.14, 64.79, 34.28, 34.16, 33.20, 33.07, 30.48, 29.61, 28.44, 28.27, 25.70, 25.69.

[0209] compound 13 The synthesis and purification procedures were the same as for compound 6. The crude product was obtained as a colorless oil. This was used in the next reaction without further purification (2.55 g, yield 94%). 1H NMR (500 MHz, chloroform-d) δ 7.72 - 7.68 (m, 2H), 7.49 - 7.45 (m, 2H), 6.99 - 6.95 (m, 2H), 6.71 (s, 2H), 4.34 - 4.20 (m, 4H), 4.07 - 3.94 (m, 6H), 3.47 - 3.39 (m, 6H), 1.96 - 1.79 (m, 12H), 1.60 - 1.45 (m, 12H), 0.38 (s, 9H).

[0210] compound 14 The synthesis and purification procedures were the same as for compound 8. The product was obtained as a dark green solid (431 mg, 40% yield). 1 H NMR (500 MHz, chloroform-d) δ 7.85 (d, J = 8.5 Hz, 4H), 7.53 (d, J = 8.6 Hz, 4H), 7.04 (d, J = 16.2 Hz, 2H), 6.98 (d, J = 16.1 Hz, 2H), 6.73 (s, 4H), 4.53 - 4.46 (m, 4H), 4.39 - 4.32 (m, 4H), 4.09 - 3.95 (m, 12H), 3.48 - 3.40 (m, 12H), 1.96 - 1.72 (m, 24H), 1.60 - 1.48 (m, 24H). 13 C NMR (126 MHz, CDCl3) δ 153.51, 152.84, 142.17, 138.93, 138.45, 136.43, 133.07, 132.35, 129.01, 127.80, 126.97, 126.90, 122.06, 113.41, 109.52, 105.55, 73.57, 69.23, 65.03, 64.87, 34.26, 34.14, 33.19, 33.07, 30.48, 29.61, 28.44, 28.27, 25.70, 25.68.

[0211] Compound COE-EDOT: The synthesis and purification procedures were the same as those for compound COE-BBT. The product was obtained as a dark green solid (181 mg, 93% yield). 1 H NMR (500 MHz, DMSO-d6, 353K) δ 7.85 - 7.80 (m, 4H), 7.69 - 7.65 (m, 4H), 7.21 (br, 4H), 6.94 (br, 4H), 4.50 (br, 4H), 4.37 (br, 4H), 4.13 - 4.04 (m, 8H), 3.99 - 3.91 (m, 4H), 3.45 - 3.35 (m, 12H), 3.13 (s, 54H), 1.86 - 1.66 (m, 24H), 1.60 - 1.49 (m, 12H), 1.46 - 1.34 (m, 12H). 13 C NMR (126 MHz, DMSO-d6, 353K) δ 153.30, 152.36, 142.64, 139.29, 138.53, 136.80, 133.09, 132.01, 129.49, 127.77, 127.38, 126.53, 120.37, 112.86, 109.21, 106.52, 73.05, 69.29, 66.19, 65.34, 64.90, 53.04, 53.01, 30.05, 29.26, 26.23, 26.10, 25.58, 25.53, 22.70.

[0212] Other COE compounds (e.g., COE-BO and COE-QX) can be synthesized similarly using the above protocol. Their structures are shown in Figure 1.

[0213] Labeling and detection of bacterial cells in flow cytometry The application of COE dyes can be extended to bacterial labeling in flow cytometry measurements. As shown in Figure 2, gram-positive bacteria, methicillin-resistant Staphylococcus aureus (MRSA), and gram-negative bacteria, Escherichia coli (E. coli), were pre-mixed in PBS at various volume ratios of 5:0, 4:1, 3:2, 2:3, 1:4, and 0:5. These bacterial mixtures were stained using COE dyes that exhibit gram selectivity and can specifically label gram-positive bacteria. Two isolated populations were observed during flow cytometry measurements. As the proportion of gram-positive bacteria decreased, the populations showing positive signals gradually decreased and disappeared when the bacterial mixture contained only gram-negative bacteria. These results not only demonstrate that the compound has the ability to distinguish between different gram-type bacterial ratios, but also reveal that the compound can be used to label bacterial samples in flow cytometry.

[0214] Labeling and detection of exosomes using flow cytometry Exosomes were prepared according to the following protocol: Exosomes were purchased from ATCC, aliquoted, and stored at -80°C. One aliquot was removed from -80°C and placed on ice. The exosomes were diluted 10-fold in cell culture grade PBS. 8 μL of the exosome suspension was mixed with 25-1 μM of COE compound. This was left on ice for 10 minutes, then diluted 100-fold in PBS to form 6x10 particles. 6 The approximate final concentrations were obtained at 1 / mL of exosomes and 25–1nM COE. The sample was briefly vortexed and used for flow cytometry. The side-scattered light (x-axis) of the violet laser was measured, and the fluorescence intensity (y-axis:λ) was measured. 励起 =405nm, 488nm, λ 発光Flow cytometry measurements were obtained by measuring wavelengths (525 nm, 690 nm). The experiments in Figures 3 and 4 demonstrate that exosomes can be successfully labeled and detected using the COE compound. Using the COE compound, exosomes can be stained with a low concentration of dye and used directly without additional purification. Figure 1 shows the structure of the compound.

[0215] [Table 1]

[0216] [Table 2]

[0217] In another example, thanks to the generosity of NanoFCM (UK), we received exosomes isolated from the SW480 colon cancer cell line and purified using size exclusion chromatography. Labeling and flow cytometry analysis were also performed by trained technicians at NanoFCM (UK). In short, the exosomes yielded approximately 10 e particles per 1 mL. 10 The exosomes were labeled at individual particle concentrations. Here, 1 μL of 10 μM COE dye solution or PKH-26 (in diluent C) was added to 9 μL of the sample to achieve a final staining concentration of 1 μM. After incubating the mixture at room temperature for 30 minutes, it was diluted 100-fold with PBS and then analyzed with a NanoAnalyzer (NanoFCM). Exosome detection was performed with a small threshold setting (68-155 S16M-Exo), and the labeled population was analyzed using the PC5 channel (Ex488 / Em670). A dye control sample was prepared using PBS instead of 9 μL of exosome solution, and the same procedure as for the exosome sample was followed for flow analysis. The results were confirmed by repeating the measurement at least twice. In another experiment, excess dye was removed from the labeled exosomes using standard ultracentrifugation before analysis as described above.

[0218] Figure 17 shows (a-e) particle size distribution plots of COE-BO, COE-BT, COE-QX, COE-BSe, and PKH26 dye-only controls (10 μM), and (f-j) corresponding gated dot plots. Figure 18 shows (a-d) particle size distribution plots of COE-labeled SW480 exosomes (10 μM), and (e-h) corresponding gated dot plots. Tables 3 and 4 summarize the results for buffered controls and COE-labeled exosomes analyzed using NanoAnalyzer.

[0219] [Table 3] [Table 4]

[0220] Figure 19 and Table 5 show the results after removing excess COE compounds from COE-labeled SW480 exosomes.

[0221] [Table 5]

[0222] Transmission electron microscopy (TEM) observation of exosomes Samples prepared for flow cytometry or collected by fluorescence-activated cell sorting (FACS) were immersed in liquid nitrogen and lyophilized. The powder was resuspended in 50 μL of cold MiliQ water. Glutaraldehyde was added to a final concentration of 2.5%. 10 μL of the sample was added to a newly glow-discharged 200-mesh Cu-carbon / Formvar grid and allowed to adhere for 10 minutes. Excess liquid was absorbed with filter paper, and the grid was washed twice with MiliQ water. The grid was stained with 2.5% gadolinium triacetate for 1 minute, and then excess liquid was absorbed with filter paper. The samples were imaged using a Tecnai G2 at 100 kV and a magnification of 30,000x. Figure 5 shows TEM micrographs of (a) exosomes, COE-BT-labeled exosomes, and c) COE-S6-labeled exosomes collected after FACS.

[0223] Labeling and detection of red blood cells (RBCs) using flow cytometry As shown in Figure 6, RBCs can be labeled for flow cell cytometry using COE compounds. RBCs (isolated from bovine whole blood, Innovative Research, Inc.) were diluted 10-fold from stock in PBS and centrifuged at 3,000 RPM for 5 minutes. The supernatant was removed and the pellet was resuspended in PBS. This was repeated a total of three times. The final pellet was resuspended in PBS to 1 vol%. 10 μM COE compound was added to the RBC suspension and incubated at room temperature for 20 minutes. The RBC-COE compound mixture was then centrifuged again at 3,000 RPM for 5 minutes. The supernatant was removed and the pellet was resuspended in fresh PBS. COE-stained RBCs and unstained RBCs were mixed in various volume ratios of 0:5, 1:4, 2:3, 3:2, 4:1, and 5:0, respectively. The resulting RBC mixtures were diluted 100-fold in PBS for flow cytometry experiments. Forward scattered light (x-axis) was measured, and fluorescence intensity (y-axis:λ) was measured. 励起 =405nm, λ 発光Flow cytometry measurements were obtained by measuring (=525nm). Figure 6 shows that two separate populations can be observed for COE compound-labeled and unlabeled RBCs. As the proportion of RBCs stained with the COE compound increases, the proportion of the population with higher fluorescence intensity also increases. This indicates the success of labeling RBCs with the COE compound and the success of detection by flow cytometry (Figure 6).

[0224] [Table 6]

[0225] Labeling and detection of mammalian cells using flow cytometry As shown in Figures 8-11, mammalian cells can be labeled for cell flow cytometry using COE. Hep-G2 and A549 (ATCC HB-8065, CCL-185) were purchased from ATCC. After receiving the frozen cells, they were thawed by gently agitating them in a 37°C water bath, and then transferred to a centrifuge tube containing 9 mL of warmed medium in DMEM + 10% FBS. The tube was then centrifuged at 200xg for 5 minutes. The supernatant was discarded, and the cell pellet was resuspended in medium in a culture flask. The cells were incubated at 37°C and 5% CO2. When cell confluence reached approximately 90%, the cells were suspended in 1× trypsin and neutralized with an equal volume of medium. After centrifugation at 200xg for 5 minutes, the supernatant was discarded, and the cell pellet was resuspended in warmed PBS containing 5-10 μM COE. The suspension was incubated at room temperature for 20 minutes, then centrifuged at 1000 rpm for 5 minutes to remove excess COE compounds. After discarding the supernatant, the pellet was resuspended in warmed PBS. COE-stained cells and unstained cells were mixed in various volume ratios of 0:5, 1:4, 2:3, 3:2, 4:1, and 5:0. The resulting suspensions were used directly in flow cytometry experiments. Forward scattered light (x-axis) was measured, and fluorescence intensity (y-axis:λ) was measured. 励起 = 561 nm, λ 発光Flow cytometry measurements were obtained by measuring the fluorescence intensity (y:λ = 610 nm). Figure 8 shows that two separate populations can be observed for COE-labeled and unlabeled cells. As the proportion of cells stained with each COE compound increases, the proportion of the population with higher fluorescence intensity also increases. This indicates the success of cell labeling with COE and the success of detection by flow cytometry (Figures 8 and 10). Figure 9 shows the proportion of flow cytometry events that occurred in the gating region of Hep-G2 stained with compounds of equation (I) in various ratios versus unstained Hep-G2. Figure 11 shows flow cytometry measurements of A549 cells labeled with 5 μM COE-BSe. Forward scattered light (x axis) was measured, and fluorescence intensity (y axis:λ) was measured. 励起 =638nm, λ 発光 Flow cytometry measurements were obtained by measuring the wavelength (=712 nm). Confluent cells were stained with 5 μM COE in PBS at room temperature for 20 minutes. The COE solution was aspirated, and the confluent cells were washed with fresh PBS. The cells were suspended in 1 × trypsin and neutralized with an equal volume of culture medium. After centrifugation at 200 x g for 5 minutes, the supernatant was discarded, and the cell pellet was resuspended in warmed PBS and used for flow cytometry. The 20% COE-labeled cell suspension was seeded and allowed to reach 90% confluence. After collecting and seeding the cells, they were used for flow cytometry for 4 passages without adding COE. (Figure 11)

[0226] [Table 7]

[0227] Fluorescence microscopy observation of mammalian cells The above experiments confirmed that COE dyes can be used to label extracellular vesicles (including exosomes), bacteria, RBCs, and mammalian cells in flow cytometry. All of these samples contain lipid bilayer structures in their membranes. To further confirm that the COE dyes target lipid membranes, colocalization of the COE compound with the commercially available membrane dye FM 4-64 was performed using confocal microscopy. As shown in Figure 12, mammalian Hep-G2 cells were stained with both 4 μM COE compound (green channel) and 4 μM FM 4-64 (red channel), and a clear staining pattern tracing the cell membrane was observed by collecting luminescence from the COE compound in the 450–490 nm range after excitation at 405 nm. The sufficient colocalization of the COE compound and FM 4-64 demonstrates that the COE dyes target lipid membranes. A549 cells were stained with 5 μM COE compound in PBS, incubated at 37°C and 5% CO2 for 1 hour, and then visualized using a fluorescence microscope. (Figure 13)

[0228] Evaluation of COE insertion into lipid bilayers using a fluorescence meter. Liposomes were prepared using the following protocol: A chloroform solution of phospholipids (e.g., POPC, POPE, and POPG) was mixed in the appropriate molar ratio and dried under a gentle nitrogen stream. The dried lipids were further dried overnight under reduced pressure to obtain thin lipid films. Small monolayer vesicles (SUVs) were prepared by mixing them with phosphate-buffered saline (PBS) at a concentration of 5 mg mL. -1 The dry film was rehydrated by adding [amount missing], and then incubated at 35°C for 2 hours with constant stirring at approximately 300 rpm. Next, the vesicles were extruded 21 times at 45°C using a 100 nm film to obtain SUV samples. The vesicles were kept at 4°C until further use.

[0229] After COE is inserted into the lipid bilayer, the luminescence of COE is significantly enhanced. Therefore, free dyes in the aqueous phase exhibit weak luminescence, low background, and are ideal for obtaining a high signal-to-noise ratio. As shown in Figure 14, both SUV (1 mg / mL) and COE-BT (10 μM) in PBS exhibit weak luminescence (λ 励起 It exhibits an emission of 520 nm. When SUV and COE-BT are mixed, the COE is inserted into the lipid bilayer. This is spontaneously caused by electrostatic and hydrophobic interactions between the COE and the lipid bilayer. As a result, a significant enhancement of luminescence is observed. For example, the luminescence intensity of the SUV and COE-BT complex increases by more than 400 times compared to the COE-BT solution at 600-630 nm. The same phenomenon is observed with COE-BBT (Figures 14 and 15). By adjusting various chemical structures, COE can achieve a wide range of emission wavelengths, from "green" to "red" and even "infrared" (Figures 14 and 15). This wide range of color options allows COE dyes to exhibit high compatibility when multiple dyes are used simultaneously.

[0230] Evaluation of COE addition regarding liposome particle size and uniformity To determine whether COE treatment alters liposome morphology (e.g., induces liposome fusion or fission), dynamic light scattering (DLS) measurements were performed using a lipid SUV model (Figure 16). SUVs were obtained after extrusion with a 100 nm membrane. During DLS measurement, a Z-mean diameter of 104.5 ± 29.45 nm and a PDI of 0.048 were observed for the 1 mg / mL SUV sample. After adding 10 μM COE-BBT to the 1 mg / mL SUV sample, the Z-mean diameter became 104.8 ± 32.65 nm and the PDI became 0.054. These DLS results indicate that COE addition does not alter liposome morphology.

[0231] The results demonstrate that the compounds of the present invention can be used across a wide range of samples, including exosomes, erythrocytes, mammalian cells, and bacterial cells. The compounds exhibit improved labeling efficiency and sensitivity through increased fluorescence intensity. These results reveal that COE can be used as a fluorescent label in flow cytometry, which primarily relies on interaction with lipid bilayers. The tunable molecular structure and ease of synthesis of COE provide broad possibilities and flexibility for tailoring to specific luminescence detection needs.

[0232] COE-labeled exosomes and their uptake into mammalian cells using imaging flow cytometry. A549 cells were placed in DMEM medium containing 10% FBS in a 6-well plate, 1 × 10⁶ cells. 5Cells were seeded at a concentration of 1 mL and allowed to adhere overnight before the experiment. The following day, 10 μg 1 mL of PC-3 exosomes or 4.5 mL of control (PBS only) was mixed with COE-Ben to a final dye concentration of 1 μM, or mixed with DiD to a final dye concentration of 2.5 μM. The samples were incubated in the dark at room temperature for 1 hour. The samples were washed by filtration using a 100 kDa cutoff centrifugation filter unit (Amicon® Ultra) and centrifuged at 2000 × g for 15 minutes to remove free dye. The concentrated samples were collected, resuspended in FBS-free DMEM medium, and divided into three aliquots. After rinsing the cells in the microplate with FBS-free DMEM medium, the stained exosomes or control (residual dye solution) were added at various time points, e.g., 2 hours, 4 hours, and 8 hours before cell collection. After exosome or dye uptake, cells were washed with warmed PBS (37°C) and 1× trypsin-EDTA was added. Cells were incubated in a 5% CO2 chamber at 37°C for up to 5 minutes. DMEM containing 10% FBS was added to a microplate, and cells were centrifuged at 200×g for 4 minutes. The supernatant was removed, and cells were resuspended in DMEM medium (containing 10% FBS), and imaged flow cytometry was performed using an Amnis ImageStreamX Mk II imaging flow cytometer. The acquisition gate was set using the area-to-aspect ratio of the bright-field channel to select only intact cellular events. For the COE-Ben channel (i.e., Ch02), cells were excited using a 405 nm laser, and emission was collected in the range of 505–560 nm. For the DiD channel (i.e., Ch05), cells were excited using a 638 nm laser, and emission was collected in the range of 642–745 nm. The bright-field region of the entire cell was used as a particle size indicator, i.e., the M04 or M01 channel. Data were processed using IDEAS v6.3. Out-of-focus cells were excluded by applying gradient RMS (root mean square) to the bright-field channel. Flow cytometry results were presented using the M04 channel (particle size) versus the Ch02 channel (COE-Ben) or Ch05 channel (DiD). Gating was set according to the unstained control sample.The "spot counting algorithm" function built into the IDEAS 6.3 software was used to count the number of bright spots within cells and was used as a metric for measuring exosome uptake. At least 1000 cells were statistically counted in each group.

[0233] Figure 20 shows (a) representative imaging flow cytometry images of A549 cells stained with COE-Ben stained exosomes at various treatments and time points, and (b-d) the corresponding flow cytometry analyses. (e) the average number of COE-Ben or DiD probe (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine 4-chlorobenzenesulfonate) spots in each cell. (f) representative imaging flow cytometry images of A549 cells after staining with COE-Ben or DiD dye residues after washing using ultrafiltration, and (g-h) the corresponding flow cytometry analyses. In imaging flow cytometry, the COE-Ben channel was excited using 405 nm and emission was collected in the range of 505-560 nm, and the DiD channel was excited using 638 nm and emission was collected in the range of 642-745 nm, with the bright-field area of ​​the entire cell used as an indicator of particle size.

[0234] Label pre-stained exosomes using COE. To distinguish between exosomes produced by A549 and exosomes derived from serum, a new cell medium for exosome production (CCM-Exo-Dep) was prepared by supplementing DMEM with exosome-depleted fetal bovine serum (Systems Biosciences, catalog: EXO-FBS-250A-1). 5 × 10⁶ A549 cells were placed in 10 mL of CCM-Exo-Dep in a T75 flask. 5 pieces mL -1After seeding and allowing to adhere for 1 hour, 2 μM COE-BT was introduced into the cell culture medium. After incubating the cells for at least 24 hours, the cell culture supernatant was collected for the first exosome production, stored at 4°C, and then purified. Without subculturing the labeled cells, 10 mL of fresh CCM-Exo-Dep was added to the cells and incubated for at least another 24 hours. Next, after 24 hours, the cell culture supernatant was collected for the second exosome production. The collected cell culture medium was first rotated at 10,000 × g for 30 minutes at room temperature to remove all necrotic cell fragments. Exosome isolation was then performed by ultracentrifugation at 100,000 × g for 1 hour at 4°C (Optima® XPN-100, Beckman Coulter). The supernatant was carefully removed, and the bottom of the centrifuge tube where the pellet was expected to be located was rinsed three times with PBS. After washing, the exosomes were pelleted again under the same conditions and then resuspended in 100 μL of PBS. After storing aliquots of purified exosomes at -80°C, downstream analysis (flow cytometry or TEM) was performed.

[0235] Figure 21 shows colocalization micrographs of A549 cells stained with early or late endosome-GFP reagent (BacMam 2.0) or 100 nM lysosome-specific dye LysoTracker® Green DND-26 after incubation with 2 μM COE-BT. COE-BT channels (represented in green) were observed by excitation at 561 nm and collection of emission in the 570–620 nm range. GFP (green fluorescent protein) and LysoTracker Green channels (represented in red) were observed by excitation at 488 nm and collection of emission in the 500–540 nm range. Pearson correlation coefficient (R) was used as the criterion for colocalization analysis using ImageJ.

[0236] Exosome samples were analyzed using transmission electron microscopy (TEM). Briefly, exosomes obtained from pre-stained A549 cells were fixed in PBS with 2.5% glutaraldehyde at room temperature for 30 minutes. 10 μL of the exosome solution was added over 15 minutes onto a newly glow-discharged Formvar carbon-coated 200-mesh copper EM grid. The sample was blotted with filter paper and washed three times with MiliQ water. The sample was negatively stained with 2% gadolinium acetate for 30 seconds. The sample was blotted with filter paper and stored overnight in a grid box in a vacuum chamber of a desiccator, and then imaged using 80kV on an FEI TENCAI G2 instrument.

[0237] Figure 22 shows (a) a transmission electron microscope image of EVs secreted from COE-BT stained A549 cells, and (b) flow cytometry analysis of EVs secreted from COE-BT stained A549 cells after the first 24 hours of incubation. The excitation and emission wavelengths for the B690 channel were set to 488 / 690 nm.

[0238] Lack of nanoparticle formation by COE Figure 23 shows (a) a photograph and (b) absorption spectra of a 50 μM COE or DiR (1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide) solution in PBS before and after ultrafiltration using a 100 K MWCO protein concentrator tube (Pierce®, Thermo Scientific®) with a relative centrifugal force of 4000. The slight decrease in the absorption spectrum of the COE sample is likely due to nonspecific binding of positively charged COE to the polyethersulfone-based ultrafiltration membrane.

[0239] Figure 24 shows (a) correlation coefficient curves of pure PBS or 1 μM COE-BT, 1 μM DiR, or 1 mM SUV in PBS, measured by dynamic light scattering (DLS). (b) Average count rate derived from DLS measurements of pure PBS or 1 μM COE-BT, 1 μM DiR, or 1 mM SUV in PBS; the experiment was repeated 5 times. (c) Correlation coefficient curves of other COEs in 1 μM of PBS, measured by DLS. (d) Average count rate derived from DLS measurements of other COEs in 1 μM of PBS; the experiment was repeated 5 times.

[0240] Figure 25 shows a photograph of the Tyndall effect of pure PBS or 10 μM COE in PBS after illumination using a red laser pointer.

[0241] Figure 26 shows (a) photographs of 200 μL of COE solution in PBS in a 96-well microplate (Costar®, polystyrene-based, Ref: 3599) before and after standing at room temperature for 16 hours. (b) photographs of 200 μL of dye solution in PBS in a 96-well microplate (Costar®, polystyrene-based, Ref: 3599) before and after standing at room temperature for 16 hours. The COE solution was obtained by diluting a 1 mM stock solution in PBS. The DiI solution was obtained by dispersing a 1 mM DiI DMSO solution in PBS with vigorous agitation. The same volume of PBS was used as a negative control.

[0242] Stability of COE in labeled vesicles using flow cytometry As described above, liposomes containing 15% POPG and 85% POPC were prepared as a stock at 5 mg / mL (or 6.564 mM) in PBS. The liposomes were extruded through a 200 nm membrane filter, and the particle size was confirmed to be approximately 140 nm by DLS. Next, separate aliquots of the stock liposomes were diluted to 1 mM and treated with 20 μM COE-Ben (or DiO) and 40 μM COE-BT (or DiD) in PBS, respectively, for 30 minutes while gently heating to 60°C. The labeled liposomes were then stored at 4°C and used in flow cytometry experiments. To demonstrate the stability of the dye in the liposomes after insertion, two separate working solutions of COE-Ben-labeled liposomes and COE-BT liposomes were first prepared, with 10 particles per 1 mL. 7 The two standard solutions were normalized to the same particle concentration of 1.5. Next, these two standard solutions were mixed in various ratios of 0:5, 1:4, 2:3, 3:2, 4:1, and 5:0, and the mixtures were incubated at room temperature for 1 hour. The undiluted mixtures were then analyzed using CytoFLEX LX (Beckman Coulter), and detection was initiated by violet side scattering (VSSC>4000). For unstained liposomes, gating was performed for COE-Ben-labeled liposomes and COE-BT-labeled liposomes using both the V525 channel (Ex405 / Em525) and the B690 channel (Ex488 / Em690), respectively. Liposomes that could contain both COE-Ben and COE-BT dyes were analyzed using the proportion of events within the double-positive region of the dot plot, suggesting dye transfer from one population to another. Furthermore, after incubating the samples overnight (24 hours) at room temperature, the same flow cytometry analysis was performed to check the stability of the dye and the degree of dye cross-leachability. The experiment was repeated twice.

[0243] Figure 27 shows flow cytometry measurements of mixtures of COE-BT stained and COE-Ben stained SUV (130 nm) in PBS, mixed at various mixing ratios, incubated for 1 hour (a-f) and 24 hours (g-l), and analyzed with Cytoflex.

[0244] Figure 28 shows the proportion of SUVs in various gates according to Figure 27 after (a) 1 hour or (b) 24 hours of mixing.

[0245] Labeling of liposomes of various particle sizes using COE The POPC solution in chloroform was mixed with a 0.5 mol% COE-Ben or COE-BT solution in chloroform, and then dried in a glass vial under a gentle argon stream. The dried lipids were further dried overnight under reduced pressure to obtain a thin lipid film. To prepare small monolayer vesicles (SUVs), PBS buffer (phosphate-buffered saline) was added to a concentration of 5 mg mL. -1 The dry film was rehydrated by adding [amount], and then incubated at 45°C for 2 hours with constant stirring at approximately 300 rpm. Next, vesicles were extruded 21 times at 45°C using 100 nm, 200 nm, 400 nm, and 800 nm films to obtain SUV samples. Then, labeled liposomes were added at a rate of 10 particles per 1 mL. 7 After dilution, the samples were analyzed using Cytoflex.

[0246] Figure 29 shows dot plot profiles of dye-positive events when POPC liposomes with particle sizes of 100 nm, 200 nm, 400 nm, and 800 nm, labeled with 0.5 mol% COE-Ben(a-d) and COE-BT(e-f), were analyzed with Cytoflex.

[0247] Figure 30 shows (a) 6.25 mg mL of PBS after being stained with 15 μM COE-Ben and 15 μM FM 4-64 at room temperature for 30 minutes. -1The image shows a confocal micrograph of the LMV (Large Multilayer Vesicle). The mixture was diluted 5-fold with PBS before confocal imaging. The COE-Ben fluorescence channel was observed by excitation at 405 nm and collection of emission in the range of 450-490 nm (shown in green), and the FM 4-64 fluorescence channel was observed by excitation at 561 nm and collection of emission in the range of 640-700 nm (shown in red). The scale bar is 20 μm. (b) The intensity curves represent the fluorescence intensity profiles of both channels on the left, shown as white lines in the fluorescence micrograph.

[0248] Figure 31 shows photographs of COE with and without (-) treatment with 1 mM SUV in PBS under ultraviolet (365 nm) irradiation using a portable ultraviolet lamp (UVP® UVLS-24 EL, 4 watts). The concentration of COE-Quin was set to 0.25 μM; the concentrations of COE-S6 and COE-Ben to 0.5 μM; the concentrations of COE-QX, COE-BO, and COE-BT to 1 μM; and the concentration of COE-BSe to 5 μM. The camera (SONY, α7R) parameters were set to ISO 8000, aperture F2.8, and exposure time 1 / 20.

[0249] Figure 32 shows (a) zeta potential measurements of SUVs with only 1 mM POPC stained with various COEs at 5 μM in DI water, and (b) Z-mean diameter and PDI of SUVs with only 1 mM POPC stained with various COEs at 5 μM in DI water, measured by DLS.

[0250] Labeling of red blood cells using COE for microscopic observation and flow cytometry analysis After removing plasma by centrifugation, red blood cells were obtained from the donor blood. Fresh or 22-day-old RBCs were used. The concentrated RBC solution was diluted 500-fold in PBS and then labeled with 2 μM COE-S6 or 1 μg / mL Cell Mask Deep Red. After incubating the cells with the dye for 10 minutes, the free dye was removed by centrifugation at 700 g for 3 minutes. The labeled cell pellet was then resuspended in 1 mL of PBS. The cells were then further diluted 10-fold in PBS and imaged on 8-well ibidi chamber slides, and analyzed for particle size and fluorescence by flow cytometry (Cytoflex).

[0251] Figure 33 shows confocal micrographs of fresh red blood cells (RBCs) labeled with (a) unstained, (b) 2 μM COE-S6, and (c) 1 μg / mL Cell Mask Deep Red. Images were acquired using the Ex405 / Em525 channel, Ex638 / Em660 channel, and bright-field channel.

[0252] Figure 34 shows confocal micrographs of erythrocytes (RBCs) stored for 22 days, (a) unstained, (b) labeled with 2 μM COE-S6, and (c) labeled with 1 μg / mL Cell Mask Deep Red. Images were acquired using the Ex405 / Em525 channel, Ex638 / Em660 channel, and bright-field channel.

[0253] Figure 35 shows FSC / SSC dot plots of flow cytometry-measured erythrocytes (RBCs) for (a) unstained, (b) labeled with 1 μM COE-S6, and (c) labeled with 0.5 μg mL-1 Cell Mask Deep Red. Unlike Cell Mask Deep Red, COE-S6 labeling does not introduce artifacts to the morphology of RBCs. (d) Histogram showing the increase in fluorescence when RBCs are labeled with gradually increasing concentrations of COE-S6, and (e) Histogram showing the decrease in fluorescence due to quenching effect when RBCs are labeled with gradually increasing concentrations of Cell Mask Deep Red. As can be seen from the coefficient of variation (Cv), i.e., spread (f) of the histogram data, COE-S6 also shows superior labeling homogeneity and uniformity.

[0254] NIR-II COE as a fluorescent probe for mammalian cells For cell detection using near-infrared fluorescence, cells were directly stained with 20 μM COE-BBT in DMEM medium and incubated overnight. After rinsing the stained cells with warmed PBS (37°C), 1× trypsin-EDTA was added. The cells were incubated in a 5% CO2 chamber at 37°C for up to 5 minutes. DMEM medium containing 10% FBS was added, and the cells were centrifuged at 200× g for 4 minutes. After removing the supernatant, the cells were resuspended in medium and subjected to flow cytometry. COE-BBT stained cells were excited using an 808 nm laser. To collect the emission signal from COE-BBT, a 900 nm long-pass filter based on UV fused silica glass was customized according to the specifications of the CytoFLEX platform optical filter (length 14.5 ± 0.1 mm, width 6.1 ± 0.1 mm, thickness 2.0 ± 0.1 mm) (Chroma, INC., China). This filter glass was mounted in the holder and used in place of the IR885 channel (Ex808 / Em885). This new channel for detecting COE-BBT fluorescence was named "IR1000".

[0255] Figure 36 shows flow cytometry measurements of COE-BBT-stained A549 cells, obtained by excitation using an 808 nm laser and collection of emission using a 950 nm long-pass filter named IR1000 channel. Unstained A549 cells were used as a negative control.

[0256] Cytotoxicity and hemolytic activity of COE A549 cells were maintained in 10% FBS-supplemented DMEM, i.e., in cell culture medium (CCM), using the usual method. A COE stock solution was prepared by dissolving solid COE in PBS to a stock concentration of 2 mM. Further dilution of the stock solution in CCM was then performed to prepare a 256 μM COE working solution. Due to the low water solubility of DiR, a DiR stock solution was prepared in ethanol. This was then diluted in CCM to prepare a 256 μM working solution. In this case, the final ethanol content was 12.8% (v / v). To test cytotoxicity, 1000 cells were seeded into a 96-well black plate with a clear optical bottom and allowed to adhere overnight in a 5% CO2 chamber at 37°C. The following day, COE / DiR solutions of various concentrations were obtained by 2-fold serial dilution in CCM (concentrations ranging from 0.5 to 256 μM) and used to replace the consumed CCM in the wells. To clarify the toxic effects derived from ethanol, identical serial dilutions were performed using pure ethanol instead of the DiR dye solution in ethanol, ensuring similar ethanol content in each well. Cells were then incubated with additives for 24 hours, after which cell viability was measured using CellTiter-Glo® (COE-Quin, COE-S6, COE-Ben, COE-BBT, DiR) or CCK-8 (COE-BT, COE-BO, COE-QX, COE-BSe) according to the manufacturer's protocol. Fluorescence (CellTiter-Glo® assay) and absorbance (CCK-8 assay) measurements were recorded using a TECAN plate reader (Spark®). The cytotoxicity assay was repeated three times.

[0257] Figure 37 shows the measured cytotoxicity of COEs against A549 cells. The IC50 values ​​of all six COEs are higher than 100 μM.

[0258] Bovine whole blood was purchased from Innovative Research in the United States. 2 mL of blood was mixed with 10 mL of PBS and centrifuged at 1,000 rpm for 5 minutes. The red blood cell pellet was collected, washed three times with PBS, and then diluted to a concentration of 2% (v / v) using PBS. Due to the slight absorption interference at 540 nm for COE-Quin, COE-S6, and COE-Ben, only COE-Quin, COE-S6, and COE-Ben were selected for this study. Each COE was dissolved in PBS and serially diluted 2-fold in a 96-well microplate. 100 μL of red blood cell suspension was mixed with 100 μL of COE solution in each well and incubated at 37°C for 1 hour with shaking (200 rpm). The microplate was centrifuged at 1,000 rpm for 10 minutes. 150 μL aliquots of the supernatant were transferred to a new 96-well microplate. Hemolytic activity was calculated by measuring absorbance at 540 nm using a multimode microplate reader (Spark®, Tecan). Triton X-100 (0.1% in PBS), which can completely lyse red blood cells, was used as a positive control, while bovine red blood cells in PBS were used as a negative control. The percentage of hemolysis was calculated using the following formula:

number

[0259] Figure 38 shows the measured hemolysis of COE against bovine erythrocytes in PBS.

Claims

【Request Item 1】 【Chemistry 1】 【Chemistry 2】 A compound selected from, or a salt or solvate thereof.

2. A method for labeling cells and / or lipid vesicles, a) The step of incubating the compound according to claim 1 with cells and / or lipid vesicles. Methods that include...

3. Lipid vesicles and / or liposomes comprising the compound described in claim 1.

Citation Information

Patent Citations

  • Fluorescent falsification-preventing gel with self-heating function, and preparation method and applications thereof

    CN110283319A

  • Distyrylarylene derivative and organic electroluminescence element

    JP2000007604A

  • Polymerizable compound having conjugated bond, liquid crystal composition, and liquid crystal display element

    JP2014224237A

  • Short conjugated oligoelectrolytes and uses thereof

    JP2021519265A

  • Methene stilbenyl-1 3 4-oxdiazole derivatives

    US3642783A